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Introduction and aims  
 Hypertensive disorders of pregnancy, in particular, pre-eclampsia, remains an enigmatic problem 
with global disease burden shared amongst industrialised and non-industrialised countries. It has 
been estimated that hypertensive disorders complicate 5 – 10% of pregnancies.
 
 The leading cause 
of maternal deaths in sub-saharan Africa is AIDS (43.7%). The Saving Mothers Guidelines for the 
tri-ennium 2005 – 2007 in South Africa found that hypertensive disorders were directly linked to 
maternal deaths in 15.7% of cases, of which 83% represents pre-eclampsia. Additionally South 
Africa now faces the challenge of obesity. These three conditions (HIV, pre-eclampsia and 
obesity) impact on each other causing adipokine dysregulation. The aim of the study was to 
examine the levels of adiponectin/leptin/TNF-α and resistin amongst non-pregnant, normotensive 
and pre-eclamptic pregnant cohorts in respect of their BMI and HIV status. 
 
Methods 
Following institutional ethical approval and informed consent, serum was obtained from a total 
of 328 women attending the RK Khan Hospital, a regional and district hospital in eThekwini, 
KwaZulu-Natal. Women were recruited into two groups ie., non-pregnant (n = 120; 36.58%) 
and pregnant  group (n = 208; 63.41%). Pregnant women were further, categorised into the 
normotensive pregnant (n = 118; 35.97%) and the pre-eclamptic (n = 90; 27.43%) groups. The 
pregnant cohort was also sub-stratified in accordance with their HIV status.  Clinical 
demographics, height, weight, body mass index (BMI), mid upper arm circumference (MUAC), 
triceps skin fold thickness were recorded. Indications and mode of delivery as well as 
associated complications, fetal ultrasound abnormalities, neonatal outcomes (APGARS), 
 xx 
weight, placental shape weight and appearance were noted. Serum was assessed by a double 
antibody sandwich ELISA technique using the DuoSet ELISA Development System for human 
adiponectin and TNF-α. Additionally, serum leptin and resistin was detected by the Bioplex 
immunoassay (Biorad). Absorbance was read spectrophotometrically at 450 nm (Systems).  
SPSS version 21 was used to analyse the demographic and experimental data. A p value < 0.05 
was considered as statistically significant. 
 
Results  
Irrespective of the HIV status, body mass index and maternal weight (p = 0.325 vs 0.138) were 
not statistically significantly different between the normotensive and pre-eclamptic groups 
respectively.  Likewise, the distribution of BMI was the same across the study groups with 
respect to HIV status (p = 0.124). 
 
Mean adiponectin levels varied between 897.93±126.18, 17.19±11.56, 23.16±21.39 and 
24.61±12.869 in the non-pregnant, normotensive pregnant, EOPE and LOPE groups respectively.  
Leptin levels varied from 4887.25±705.29, 2732.27±580.18, 955.75±527.64 and 310.23±177.43 in 
the non-pregnant, normotensive pregnant, EOPE and LOPE groups respectively.  TNF-α was 
undetected in the non-pregnant group as compared to 608.52±84.89, 661.03±202.60 and 
616.43±117.53 in the normotensive pregnant, EOPE and LOPE groups respectively. Resistin 
varied from 7497.13±1921.95 in the non-pregnant group compared to 3536.50±730.04, 




The levels of TNF-α, leptin and resistin were significantly different within the normotensive 
pregnant versus pre-eclamptic groups. Except for adiponectin (p < 0.292); TNF-α (p < 0.044), 
leptin (p < 0.004) and resistin (p < 0.006) were statistically significantly different within the 
pregnant cohorts. The study demonstrated statistically significant differences in adiponectin/ 
leptin/ TNF-α and resistin between non-pregnant, normotensive and pre-eclamptic cohorts with 
respect to HIV status and BMI. There were significant differences in the levels of 
adiponectin/leptin/resistin and TNF-α with respect to HIV status (p=0.00). Additionally, a 
statistically significant difference in the level of adiponectin in the non-pregnant as compared to 
the normotensive cohorts (p<0.00) was noted. Furthermore,, there were statistically significant 
differences in the levels of TNF-α, leptin and resistin in the normotensive as compared to pre-
eclamptic cohorts (p<0.000). This study was able to depict baseline adiponectin / leptin / resistin 
and TNF-α levels according to BMI in the local population. 
 
Conclusion 
This study was expedient in the fact that patients were all standardized according to ethnicity, sub-
analysed according to BMI and all samples taken from the third trimester of pregnancy – one of 
the first such studies to be performed within South Africa as well as globally.  This study reports 
significant differences in the BMI of the non-pregnant and pregnant groups, but no significant 
differences within the pregnant cohorts.  In conclusion this study establishes an adipokine baseline 
for future reference with regards to South African Black pregnant and non-pregnant women.  
Albeit at term, the study shows a statistically significant difference in the levels of 
adiponectin/leptin/resistin and TNF-α in HIV positive patients within the non-pregnant versus 
pregnant population. Within the pre-eclamptic cohort there was no statistically significant 
difference in EOPE versus LOPE.  
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CHAPTER ONE 
BACKGROUND AND LITERATURE REVIEW 
 
1.1 NORMAL PREGNANCY 
Pregnancy is a unique condition in that a growing fetus with its own foreign genetic make-up 
requires nutritional support from the mother, however direct maternal leucocyte interaction 
with fetal cells creates a hostile milieu.  This hurdle is overcome via the placenta, which plays a 
critical role at the materno-fetal interface.  
 
Placental development is a highly specialized series of events critical for normal fetal growth 
and development. Some of the essential roles of the placenta include formation of the materno-
fetal interface preventing rejection of the fetal allograft, allowing gaseous exchange, transport 
of nutrients/excretion of fetal waste and acting as an endocrine organ releasing peptides and 
hormones (Fig.1.1)(Jansson and Powell, 2000, Cunningham et al., 2009).  
 




 - 2 - 
1.2 PLACENTATION AND EARLY DEVELOPMENT 
The development of the fetus and placenta is a continuum of events commencing at 
fertilisation. Post fertilisation, the zygote (Fig 1.2a) undergoes rapid mitosis (Fig 1.2b) to form 
the morula (Fig 1.2c), which on day 5, enters the uterus and forms the blastocyst. The 
blastocyst becomes a fluid filled cavity and allows polarisation of cells (Fig 1.2d). The 
formation of the human placenta begins with the trophectoderm, which is the first tissue to 
differentiate at the morula stage of development, giving rise to a layer of trophoblastic cells 
encircling the blastocyst (Cunningham et al., 2009; (Marieb, 2003). The outer trophoblastic 
layer of the blastocyst goes on to form the placenta and fetal membranes. On day 6, 
implantation entails movement of the blastocyst to an optimal position (usually the mid to 
upper anterior or posterior uterine wall), adhesion and invasion into the uterine wall (Fig 1.2e) 
where it has access to the glycogen nourishment (Cunningham et al., 2009, Marieb, 2003). 
 
 
Figure 1.2: Schematic diagram illustrating stages of cleavage of the zygote, to form the 
blastocyst. Adapted from (Marieb, 2003). 
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As the trophoblast erodes deeper into the decidua, vacuoles form and become confluent to form 
lacunae by day 13. The lacunar space in due course becomes the intervillous space.  The stem 
cell line of the placenta is the progenitor cytotrophoblasts (CT). Differentiation of CTs occur 
along one of two pathways, ie formation of the villous cytotrophoblast ultimately forming the 
syncytiotrophoblast (ST) or the extravillous cytotrophoblast (EVT) layer (Cunningham et al., 
2009).  
 
The specialised syncytiotrophoblast has several functions, including transport of gases, 
nutrients, and waste products and synthesis of peptide and steroid hormones that regulate 
placental, fetal, and maternal systems. Extravillous trophoblasts have both a proliferative and 
invasive cohort. There is also a migratory EVT, which is neither invasive nor proliferative. 







 week of pregnancy the EVT erupts into 2 columns with a proliferative 
aspect at the base and invasive aspect at the distal portion of the column. Invasive EVTs that 
invades the decidua are called interstitial EVTs, whereas those that invade and remodel the 
spiral arteries are called endovascular EVTs. Endovascular invasion (intramural or intra-
arterial) involves replacement or displacement of vascular smooth muscle and endothelial cells 
with a flaccid fibrinoid type material. This leads to transformation of the narrow spiral arteries 
into wide bore utero-placental arteries/sinusoids.  This physiological conversion of a small 
calibre spiral artery into a large bore flaccid conduit with a low resistance high flow supply of 
blood, ensures oxygen and nutrient demands of the fetus are met (Kaufmann et al., 2003). 
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1.2.1 Other functions of EVTs 
Extravillous trophoblast cells express specific proteins defining the stage and role of the 
differentiation and invasion process. These include integrin cell-extracellular matrix antigens, 
matrix metallo-proteinases (MMPs), signal transduction proteins such as transforming growth 
factor-ß (TGF-ß), vascular endothelial growth factor (VEGF) and VEGF receptors, and insulin-
like growth factor 2 (IGF2) (Kaufmann et al., 2003). 
 
Invasion of the decidua and myometrium by the EVT is achieved with degradation of the 
extracellular matrix by means of several members of the MMP protease family. The activity of 
these MMPs is regulated by their tissue inhibitors (TIMPs) (Huppertz et al., 1998, Kaufmann et 
al., 2003, Huppertz et al., 2006, Xu et al., 2000, Lunghi et al., 2007). TIMP-1, an inhibitor of 
all MMPs, and TIMP-2 have been found in decidual cells (Charnock-Jones and Burton, 2000, 
Caniggia et al., 1999) and EVTs (Wolf et al., 1991, Liu et al., 2012, Kaufmann et al., 2003). 
Hepatocyte growth factor (HGF) stimulates trophoblast invasion via the met receptor and 
induction of MMP-9. The decidua prevents uninhibited EVT invasion by secreting locally 
acting factors (cytokines, protease inhibitors), which modulate trophoblast invasion (Huppertz 
et al., 1998, Plaisier, 2011). 
 
Metabolic and endocrine function is a tightly controlled orderly process in healthy pregnancies. 
The placenta is not innervated, and hence any communication between it, the mother, and the 
fetus must involve humoral agents. The signalling molecules from the placenta act locally 
through paracrine and autocrine regulation. The hormones produced by the placenta can be split 
into two categories: peptide hormones (human chorionic gonadotropin [hCG], human placental 
lactogen [hPL], cytokines, growth hormone [GH], insulin-like growth factors [IGF's], 
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corticotropin releasing hormone [CRH], vascular endothelial growth factor [VEGF], placental 
growth factor [PIGF]) and steroid hormones (estrogens, progesterone and glucocorticoids) 




Figure 1.3: Diagram illustrating the concept of two waves of trophoblastic invasion into the 
spiral artery. On the left hand side one can see the endovascular trophoblast migration into the 
decidual segments of the spiral arteries which occurs during the first trimester. On the right 
hand side which is illustrating a second semester spiral artery, this endovascular migration is 
seen extending into the myometrial segments the of the spiral arteries. In addition, the 
intramural trophoblast invasion which transforms the vessel walls and alters vasoreactivity is 
illustrated. Red arrow: direction of blood flow; black arrow: direction of endovascular 
trophoblast migration.  Adapted from (Pijnenborg et al., 2006). 
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1.3 HYPERTENSIVE DISORDERS OF PREGNANCY 
Hypertensive disorders of pregnancy, in particular, pre-eclampsia, remain an enigmatic 
problem with global disease burden shared amongst high and low income countries. It has been 
estimated that worldwide, hypertensive disorders complicate 5 – 10% of all pregnancies 
(Cunningham et al., 2009). The recent South African Saving Mothers Guidelines for the tri-
ennium 2008 –2010 demonstrates that hemorrhage and hypertensive disorders of pregnancy are 
the commonest direct cause of maternal deaths (2012 Saving Mothers). Additionally, their 
previous report for the tri-ennium 2005 – 2007, 83% of maternal deaths were attributed to pre-
eclampsia (NCCEMD, 2007).  
 
1.3.1 Classification and characteristics of hypertensive disorders 
Pre-eclampsia is part of a spectrum of hypertensive disorders that may complicate pregnancy. 
As specified by the National High Blood Pressure Education Program (NHBPEP) Working 
Group (National High Blood Pressure Education Program Working Group on High Blood 




a) Gestational hypertension 
Gestational hypertension is characterised by: 
 BP of 140/90 mm Hg or greater on 2 separate occasions at least 6 hours apart after 20 
weeks gestation 
 Proteinuria < 0.3 g/24 h 
 BP returns to normal less than 6 weeks' postpartum 
 The final diagnosis is only confirmed once the postpartum period is complete 
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b) Chronic hypertension 
Chronic hypertension may be diagnosed when:   
(a) BP 140/90 mm Hg or greater occurs before pregnancy or diagnosed before 20 weeks' 
gestation; not attributable to gestational trophoblastic disease or  
(b) there is hypertension first diagnosed after 20 weeks' gestation and persistent after 12 weeks’ 
postpartum.  
 
Preexisting chronic hypertension may present with superimposed pre-eclampsia presenting as 
new-onset proteinuria after 20 weeks' gestation.  
 
c) Pre-eclampsia/eclampsia 
Pre-eclampsia/eclampsia is diagnosed with a BP of 140/90 mmHg or greater measured on 2 
separate occasions at least 6 hours apart after 20 weeks' gestation in women with previously 
normal BP. The presence of proteinuria (≥ 0.3 g protein in 24 h urine specimen) is also a 
prerequisite.  
 
Eclampsia is defined as seizures that cannot be attributable to other causes, in a woman with 
pre-eclampsia. 
 
d) Superimposed pre-eclampsia 
Superimposed pre-eclampsia (on chronic hypertension) is characterized by:  
(a) the new onset of proteinuria (≥300 mg/24 h) in a woman with hypertension but no 
proteinuria before 20 weeks' gestation or;  
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(a) a sudden increase in proteinuria or BP, or a platelet count of less than 100 000/mm
3
, in a 
woman with hypertension and proteinuria before 20 weeks' gestation.  
 
1.3.2 Pre-eclampsia 
Pre-eclampsia is a systemic pregnancy syndrome that is typically characterised by new onset 
hypertension ie., blood pressure (BP) ≥ 140/90 mmHg on two separate occasions at least six 
hours (h) apart) after 20 weeks gestation in the presence of proteinuria (with proteinuria defined 
as the urinary excretion of ≥ 300 mg protein in a 24 h urine collection) (National High Blood 
Pressure Education Program Working Group on High Blood Pressure in, 2000).  Blood 
pressure returns to normo-tension within 6 weeks’ following delivery. It is a multi-organ 
disease, characterised by a generalised endothelial dysfunction and an exaggerated systemic 
inflammatory response (Redman and Sargent, 2005).  Pre-eclampsia is associated with a 
shallow trophoblast invasion of spiral arteries (Kaufmann et al., 2003). A consequence of this 
lack of physiological conversion of the maternal spiral arteries, is that they remain small bore 
conduits hence there is restricted oxygen and nutrient supply to the fetus (Kaufmann et al., 
2003).  The resulting hypoxia triggers the clinical symptoms of pre-eclampsia. The only 
effective intervention to reverse the syndrome is delivery of the placenta.  
 
1.3.3 Clinical parameters for pre-eclampsia diagnosis 
 
a) Blood pressure 
Blood pressure must be measured with the parturient in a seated position and the right upper 
arm lying at the level of the heart. The paturient should not be in a decubitus position, so that 
the arm is above the right atrium. The blood pressure is taken according to the Korotkoff 
sounds (Shennan et al., 1996). 
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The correct cuff size is dependent on the mid upper arm circumference: 
 for arm circumference of up to 33 cm – standard size (13x23 cm) 
 for arm circumference between 33 - 41 cm – large size (33x15 cm) 
 for an arm circumference of 41 cm or more – a thigh cuff (18x36 cm) 
 use a larger cuff  rather than too small a cuff size,  minimize errors (Milne et al., 2005) 
 













b) Urine tests 
Proteinuria is defined as the presence of at least 300 mg of protein in a 24 h urine sample 
(Schroeder, 2002). Additionally, significant proteinuria should be diagnosed on a 24 h urine 
total protein collection preferably. Studies show that up to 30% of supposed gestational 
hypertensive patients diagnosed on the basis of trace proteinuria on random clean catch 
midstream urine have 300 mg of protein on a 24 h urine total protein (Andrus and Wolfson, 
2010). However a finding of 1+ proteinuria on a clean-catch mid-stream urine is sufficient to 
make a diagnosis of significant proteinuria.  
 
Korotkoff sound Auscultation   Implication 
I Clear cut snapping tone Systolic blood pressure 
II Succession of murmurs  
III Disappearance of murmurs  
IV Muffling of sounds Diastolic BP in pregnancy 
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There may also be a role for the use of protein-creatinine ratio in the diagnosis of proteinuria 
using random urine samples. Values of 0.14 – 0.3 mg have been used to diagnose proteinuria. 
There is no consensus as to the best threshold for diagnosis of significant proteinuria. 
 
However, up to 10% of pre-eclamptics and 20% of eclamptics are aproteinuric (Waugh et al., 
2005); (Durnwald and Mercer, 2003). The HELLP syndrome may also occur in the absence of 
proteinuria. Hyperuricaemia may be one of the earliest manifestations of pre-eclampsia, 
however the sensitivity is low (0 – 55%) whilst the specificity is relatively high (77 – 95%) 
(Buhimschi et al., 2009). Baweja et al (2011) suggested measuring spot urinary albumin: 
creatinine ratio (ACR) values (Baweja et al., 2011).  If measured early in the second trimester, 
an ACR of 35.5 mg/mmol or higher may predict pre-eclampsia before clinical symptoms 
develop (Baweja et al., 2011).   
 
 
1.3.4 Classification  
Pre-eclampsia may be sub classified according to the stage of placentation: 
a) Early onset pre-eclampsia (< 34 weeks; EOPE):  these individuals are characterised by 
abnormal placentation (as interstitial and endovascular trophoblastic invasion is 
completed within 15 weeks of gestation).  
 
b) Late onset pre-eclampsia (> 34weeks; LOPE):  is more often associated with adequate 
placentation but excessive foetal demands.  
 
Early onset pre-eclampsia is associated with  a four-fold increased risk of stillbirth in 
subsequent pregnancy as compared to no elevated risk of stillbirth in women with late onset 
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disease (Scherer et al., 1995).  Comparison of 456 668 singleton deliveries between early and 
late onset pre-eclamptics has revealed that the rate of all adverse birth outcomes, except for 
large for gestational age (LGA), were significantly higher amongst women with EOPE 
compared with women without early-onset disease (Lisonkova and Joseph, 2013). Amongst the 
women with EOPE, approximately 12% delivered at 34 weeks' gestation or later, and almost 
one half of babies (49.5%) were very low ie., birth weight < 1500 g. With the exception of 
neonatal death rates, all other adverse birth outcomes were significantly higher among mothers 
with LOPE compared with those without pre-eclampsia. 
 
Notably the rate of fetal death is approximately 6 times higher, whilst the rate of perinatal death 
or serious neonatal morbidity is 16 times higher amongst women with EOPE (Lisonkova and 
Joseph, 2013). 
 
Alternatively, pre-eclampsia may be sub-classified on the severity of blood pressure (National 
High Blood Pressure Education Program Working Group on High Blood Pressure in, 2000): 
     
  a) Mild pre-eclampsia is generally considered to be a BP ≥ 140/90 mmHg on 2 
occasions, at least 6 hours apart, but without evidence of end-organ damage, in a woman 
who was normotensive before 20 weeks' gestation. In a patient with pre-existing essential 
hypertension, superimposed pre-eclampsia is diagnosed if systolic blood pressure (SBP) 
has increased by 30 mmHg or if diastolic blood pressure (DBP) has increased by 15 
mmHg. 
b) Severe pre-eclampsia is defined as SBP of 160 mmHg or higher or DBP of 110 mmHg 
or higher on 2 occasions at least 6 hours apart, with or without proteinuria of more than 5 g 
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in a 24-h collection or more than 3+ on 2 random urine samples collected at least 4 hours 
apart; pulmonary edema or cyanosis; oliguria (< 400 mL in 24 hours); epi-gastric pain 
and/or impaired liver function; thrombocytopenia and oligohydramnios. 
 
       c) Decreased fetal growth or placental abruption Decreased fetal growth is the failure of 
the fetus to achieve expected growth norms as established by ethnic specific growth charts. 
Placental abruption is the premature separation of a normally situated placenta from the 
uterine wall prior to the delivery of the baby. 
 
1.3.5 Risk factors for pre-eclampsia  
1. Primiparity – a meta-analysis of 26 eligible studies found a summary odds ratio (OR) 
for PE in primiparous women compared to their multiparous counterparts of 2.42 (95% 
CI: 2.16- 2.71) with a range of 1.4 to 5.5 (Luo et al., 2007)
 
. 
2. Previous pre-eclampsia – a previous normal pregnancy is associated with a reduced 
incidence of PE in a subsequent pregnancy (Trogstad et al., 2001), however previous 
PE is a strong risk factor for PE in multiparous women. The recurrence risk is about 
14%. 
3. Maternal pre-pregnancy body mass index (BMI) – High BMI is consistently found to 
increase PE risk. The odds ratio in obese women (BMI > 30 units) is reported to vary 
from 3 - 5 compared to their normal weight counterparts (Duckitt and Harrington, 
2005). This finding however is mainly associated with LOPE rather than EOPE. 
4. Underlying medical conditions – conditions associated with endothelial damage e.g. 
diabetes mellitus, antiphospholipid antibodies, autoimmune or renal disease, are 
associated with increased risk of PE development (Chappell et al., 2008). Chronic 
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hypertension is an important risk factor for the development of superimposed PE 
(Conde-Agudelo et al., 1999). 
5. Smoking in pregnancy – this is associated with a reduced risk of PE development (OR: 
0.5 - 0.8) compared with non-smokers (England and Zhang, 2007, Sibai et al., 2000). 
6. Pregnancy specific factors – multiple gestations carry a two to three time’s greater risk 
for PE development compared with singleton gestations (Prasannan-Nair et al., 2006). 
Twin and molar pregnancies are associated with greater placental mass, the subsequent 
increased placental debris is believed to result in a maternal systemic inflammatory 
response, lowering the threshold for PE development (Wong et al., 2007, Mbah et al., 
2010).  Alternatively the increased paternal genetic contribution may be an explanation. 
Glutathione S-transferase P1-1 is a major biotransformation enzyme in placenta and 
decidua. The 105I Le→Val polymorphism in the glutathione S-transferase P1 gene is 
associated with lower enzyme detoxification capacity. This polymorhism is contributed 
by paternal genes and may lead to pre-eclampsia (Zusterzeel et al., 2002, Zusterzeel et 
al., 2001). 
7. Ethnicity – Black nulliparous women carry twice the risk of developing PE compared to 
Whites (ACOG, 2002). 
 
Heterogeneity of the disease has been suggested by numerous studies, however the exaggerated 
inflammatory response noted in pre-eclampsia, is now speculated to be due to either an 
excessive placental stimulus or due to an overactive maternal response to a normal placental 
stimulus (Figure 1.1).   Focus has recently shifted to adipokines and their possible relationship 
to the development of pre-eclampsia. 
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1.3.6 Placentation in pre-eclampsia  
Abnormal trophoblastic invasion of the uterine vessels is considered the main protagonist of the 
pre-eclampsia syndrome (Ishihara et al., 2002). Studies have shown an inverse correlation 
between the degree of spiral arteriole invasion and the severity of the pre-eclampsia (Ishihara et 
al.; 2002). Because of the placental hypo-perfusion following incomplete trophoblastic 
invasion as a result of the release of systemic vasoactive compounds there is an exaggerated 
inflammatory response, vasoconstriction, endothelial damage, capillary leak, 
hypercoagulability, and platelet dysfunction, all contributing to organ damage and the clinical 
manifestations of the disease.  
 
The shallow placentation results from the fact that the invasion of the decidual arterioles by 
cytotrophoblasts is incomplete which may in itself arise from failure in alteration of the 
molecular expression necessary for the differentiation of the cytotrophoblasts, as required for 
pseudovascularization.  
 
The invasive cytotrophoblasts fail to replace the tunica media, which means that the mostly 
intact arterioles capable of vasoconstriction are still present. Previous studies evaluating the 
histology of the placental bed demonstrates few cytotrophoblasts beyond the decidual layer.  
 
Dramatic changes in trophoblast differentiation occur in various pathophysiological situations 
and may underlie pregnancy disorders, such as pre-eclampsia and fetal growth restriction 
(IUGR). Interstitial EVT density, however, does not differ between normal pregnancy and pre-
eclampsia. Compared to the minimal EVT apoptosis seen in normal pregnancy, in pre-
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eclamptics it has been found that 15 - 50% of cells are apoptotic, a finding associated with 
macrophages around spiral arteries (Myatt, 2002, Lyall and Myatt 2002).  
 
In normal pregnancy, shedding of syncytiotrophoblast fragments into the maternal circulation 
(approximately 100 000 fragments/day) as a result of apoptosis or necrosis, does not elicit a 
maternal immune response. However, the rate of syncytiotrophoblast apoptosis is increased 
from 2 - 3%  in normal pregnancy to 5 - 6% in pregnancies complicated by IUGR (Ishihara et 
al., 2002) or pre-eclampsia (Leung et al., 2001).  
 
Additionally, in a recent study, the protein expression of the anti-angiogenic soluble fms-like 
tyrosine kinase receptor (sFlt1) and soluble endoglin (sEng) was found to be increased in 
contrast to the proangiogenic placental growth factor and transforming growth factor beta 1 in 
pre-eclamptic compared with normotensive pregnancies, irrespective of the HIV status 




Human pregnancy is typified by endocrine and metabolic maternal adaptations including 
increase in weight, body fat mass, and insulin resistance (Cunningham et al., 2009).  These 
changes reflect a physiological adaptation necessary to meet the energy demands of the fetus 
and prepare the mother for delivery and lactation. Adipose tissue is recognised as both a 
metabolic and endocrine organ, secreting several proteins such as adiponectin, leptin, resistin, 
and tumor necrosis factor alpha (TNF-α).  During pregnancy, the placenta is an additional 
source of these proteins.  
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1.4.1 Adiponectin 
Adiponectin is also known as adipocyte complement-related protein of 30 kDa (ACRP30), 
adipoQ, adipose most abundant gene transcript 1 (apM1), and gelatin-binding protein of 28 
kDa (GBP28). It is an adipocyte-specific, secreted protein with roles in glucose and lipid 
homeostasis. Circulating adiponectin occurs in relatively high concentrations of 5-30 µg/ml, 
and occupies 0.01% of plasma proteins (Ukkola and Santaniemi, 2002). The hormone reflects 
sexual dimorphism and is inversely correlated with percentage of body fat in adults (Gable et 
al., 2006). This hormone has been found to be an insulin sensitising factor, modulating the 
endothelial inflammatory response with a direct anti-arthrogenic effect (Nakatsukasa et al., 
2008).  
 
Adiponectin itself is encoded on chromosome 3q27, a region that has been highlighted as 
affecting genetic susceptibility to non-insulin dependent diabetes mellitus and obesity (Mori et 
al., 2002).   Adiponectin exerts its insulin-sensitizing action via its reducing hepatic glucose 
production and enhancing insulin activity in the liver. Its circulating levels are downgraded in 
insulin-resistant states such as obesity and type 2 diabetes.(Yamauchi et al., 2002, Kadowaki et 
al., 2007).  
 
1.4.1.1 Adiponectin structure 
Structurally, adiponectin is a 244 amino acid (aa) long polypeptide with four distinct regions,  
a)  a short signal sequence that targets the hormone for secretion outside the cell,  
b) a short species specific aa sequence,  
c) a 65 aa with similarity to other collagenous proteins and,  
d)  a globular domain.  
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Adiponectin self-associates into large structures, the protein trimers continue to self-associate 
to form hexamers/dodecamers (Figure 1.5). The full length (fAd) can be proteolytically 




Figure 1.5: Structure of adiponectin (Goldstein et al., 2009) 
 
1.4.1.2 Receptors for Adiponectin 
The receptors for adiponectin, AdipoR1, and AdipoR2, have distinct expression patterns and 
bind to the different adiponectin isomers with different affinities. AdipoR1, expressed with the 
highest levels in skeletal muscle, primarily binds globular forms of adiponectin. AdipoR2, 
mainly expressed in the liver, binds fAd with higher affinity than gAd.  
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1.4.1.3 Adiponectin in pregnancy 
Data on the circulating levels of adiponectin in pre-eclamptic women are contradictory. Some 
studies have shown that serum levels of adiponectin are higher in women with pre-eclampsia 
compared to normal healthy pregnant women (Ouyang et al., 2009); (Haugen et al., 2006); 
(Hendler et al., 2005a); (Kajantie et al., 2005); (Lu et al., 2006); (Naruse et al., 2005); (Ramsay 
et al., 2003). Conversely, low serum levels of adiponectin have also been reported in pre-
eclampsia (Hendler et al., 2005b); (Cortelazzi et al., 2007); (D'Anna et al., 2005); (Suwaki et 
al., 2006). Others have shown no difference in circulating concentrations of adiponectin 
between normotensive pregnant women and pre-eclampsia (Degawa-Yamauchi et al., 2003). In 
pregnancy adiponectin levels range between 2.7– 25 µg/ml (Nien et al., 2007) whilst in the 
non-pregnant group adiponectin levels range between 3.5 – 22.4 µg/ml.  They also 
demonstrated that no difference in adiponectin concentrations was found between non-pregnant 
and overweight pregnant females at all gestational ages  (Nien et al., 2007). 
 
Moreover, they demonstrated a significantly lower adiponectin concentration in overweight 
pregnant women compared to their normal weight counterparts. Notably, adiponectin levels 
significantly decreased with advancing gestational age (Nien et al., 2007). Table 1.2 - 1.3 
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Table 1.2: Plasma adiponectin concentrations (μg/mL) in normal weight (BMI<25) pregnant 
women. 
GA 10th percentile 25th percentile 50th percentile 75th percentile 90th percentile 
11–14 weeks 5.6 7.7 10.2 12.9 17.4 
15–18 weeks 4.8 7.6 9.5 11.9 14.8 
19–22 weeks 5.7 7.2 9.0 11.5 14.6 
23–26 weeks 5.6 7.2 8.6 10.8 14.1 
27–29 weeks 4.2 6.4 8.3 10.9 12.2 
31–34 weeks 4.6 5.5 8.2 10.4 12.2 
>37 weeks 5.0 6.7 8.6 11.3 13.4 
 
Table 1.3: Plasma adiponectin concentrations (ug/mL) in overweight BMI>25 pregnant women 
GA 10th percentile 25th percentile 50th percentile 75th percentile 90th percentile 
 
11–14 weeks 4.2 6.2 7.9 9.7 11.9 
15–18 weeks 5.3 7.1 8.2 11.2 16.1 
19–22 weeks 4.3 5.4 6.5 8.4 12.2 
23–26 weeks 4.8 5.7 6.7 9.5 12.4 
27–29 weeks 4.3 4.6 7.5 9.7 13.9 
31–34 weeks 4.9 5.6 6.5 8.3 9.6 
>37 weeks 5.1 6.0 7.2 9.1 11.3 
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The limitation of the latter study however, was that the samples were randomly drawn from the 
NIH sample bank.  Results were confounded by race, diet and sub-categorisation for 
complicated pregnancies and their effect on adiponectin levels. 
 
Adiponectin has been found at the feto-maternal interface during the process of spiral artery 
remodelling. Although preceding reports suggest it is produced and secreted by the human 
placenta, more contemporary studies cast doubt on these initial observations (Caminos et al., 
2005, Chen et al., 2006, Corbetta et al., 2005, Pinar et al., 2008).  These reports demonstrate 
that human first trimester trophoblasts express AdipoR1 and AdipoR2 receptors through which 
adiponectin exerts its function and influences placental functions (Tie Weiwei et al., 2009).  
 
1.4.2 Leptin 
Body weight is synchronized by a complex system, including both peripheral and central 
factors. One of the two hormones that plays an important role in the adaptation of food intake 
and body weight is leptin. Leptin is an important hormone in satiety and fatty acid oxidation 
and is directly correlated with the percentage of body fat (Henson and Castracane, 2006). It is 
secreted by adipose tissue in a pulsatile mode usually 2–3 h after meals at a frequency 
dependent on the adipose tissue mass. Circulating leptin levels (normal range: 1–15 ng/mL) 
diametrically reflects the amount of energy stored in the adipose tissue and is proportionate to 
the body adipose mass. 
 
In 1994, the human obese (OB) gene and its product leptin was identified and characterized 
(Zhang et al., 1994b). The OB gene is located on chromosome 7 (7q31.3) and is composed of 
three exons and two introns spanning 18 kb (Masuzaki et al., 1995, Isse et al., 1995); (Gong et 
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al., 1996). It encodes a protein consisting of 166 amino acids with a putative signal sequence 
(Masuzaki et al., 1995). Only one OB mRNA species has been found in abundance in human 
adipose tissues (Masuzaki et al., 1995). 
 
1.4.2.1 Leptin structure 
Human leptin is a 167 aa protein, manufactured primarily in white adipose tissue and is directly 
proportional to total body fat content (Fig. 1.6). Leptin acts on the central nervous system, in 
particular the hypothalamus, suppressing food intake and stimulating energy expenditure (La 
Cava et al., 2004). Additionally, it is produced in the placenta, ovaries, mammary tissue and 
liver.  It is a pro-inflammatory cytokine that belongs to the type I cytokine superfamily and has 
structural similarity with interleukin-6 (La Cava et al., 2004). 
  
1.4.2.2 Leptin receptors 
Leptin acts through the leptin receptor (LEPR or OBR).  The OBR gene is located on 
chromosome 1 (1p31), is constituted of 18 exons and 17 introns, and encodes a protein 
consisting of 1162 amino acids (Chung et al., 1996); (Meier and Gressner, 2004). One of the 
splice variants of the OBR gene, the one with the longest intracellular domain (OB-Rb) and full 
signalling capabilities, is widely expressed in the human brain (Campfield et al., 1996); 
(Burguera et al., 2000); (Hegyi et al., 2004)). OB-Rb is highly expressed in the hypothalamus 
and cerebellum (Burguera et al., 2000);  (Considine et al., 1996). In addition, the leptin 
receptor is expressed in other tissues, such as the human vasculature, stomach and placenta 
(Sobhani et al., 2000); (Henson et al., 1998); (Sierra-Honigmann et al., 1998). Both long and 
short leptin receptor (OBR) isoforms are present in placenta, and are co-localized with leptin to 
the syncytiotrophoblast at the maternal interface (Bodner et al., 1999). 
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1.4.2.3 Leptin and pregnancy 
Recent studies suggest that leptin is essential to trophoblastic proliferation and survival, as well 
as to regulating cell proliferation, inhibiting apoptosis, stimulating protein synthesis and 
regulating fetal growth and development (Postovit et al., 2001, Otero, 2005). In a recent study, 
a direct relationship between leptin and BMI, but not between leptin and pre-eclampsia was 
noted (Hendler et al., 2005a).  The correlation  of leptin levels with pre-eclampsia were 
investigated by others as well  (Kafulafula et al., 2002); (Arita et al., 1999). 
 
In contradiction to the aforementioned studies, an increase in leptin levels in pre-eclamptic 
patients was noted (McCarthy et al., 1999); (Ning et al., 2004); whilst Khosrowbeygi and 
Ahmadvand (2013) showed a significant increase in the leptin/adiponectin ratio in pre-
eclamptic Bangladeshi women (Khosrowbeygi and Ahmadvand, 2013). However, all the above 
studies were small in number and could not be generalised to the local population. They also 
failed to take into account possible effects of HIV and antiretroviral drugs.  
 
 
Figure 1.6: Leptin attaching to adipose tissue as depicted by (Andrade, 2014) 
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1.4.3 Resistin 
Resistin is a cytokine that was discovered in 2001 by Steppan et al., (Steppan, 2001). Resistin 
circulates at high concentrations in diet-induced and genetic varieties of obesity and has been 
found to modulate insulin action on hepatic glucose (Chen et al., 2005).  Circulating levels of 
resistin are proportional to adiposity.  High levels of resistin have been observed in normal 
pregnant women at term, while this increase is less evident in women with PE (Milan et al., 
2002). 
 
Resistin itself is a cysteine-rich protein that is encoded by the RETN gene in humans. It is a 
signalling molecule expressed in monocytes, macrophages and adipocytes. In adipocytes, 
resistin gene expression is induced during fat cell differentiation.  Resistin has been shown to 
increase transcriptional events, leading to an increased expression of several pro-inflammatory 
cytokines including (but not limited to) interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-12 
(IL-12), and tumour necrosis factor-α (TNF-α) (Silswal et al., 2005, Maffei et al., 1995). 
 
1.4.3.1 Structure and synthesis 
Human resistin, a 12.5-kDa protein, contains 108 amino acids as a propeptide. Its hydrophobic 
signal peptide is cleaved before its secretion. Resistin circulates in human blood as a dimeric 
protein consisting of two 92-amino acid polypeptides that are linked by a disulfide bridge 
(Aruna et al., 2003) at Cys-26. Holcomb et al. first described the gene family and its tissue-
specific distribution (Holcomb et al., 2000). By comparison of bronchoalveolar lavages from 
control mice with lavages from mice subjected to experimentally induced asthma, they 
identified, by microsequencing, a protein that was up-regulated in the asthmatic lung. This 
novel protein, FIZZ1 (found in inflammatory zone 1) is also known as resistin-like molecule α 
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(RELMα). One of two additional homologs, FIZZ2, also known as RELMβ, was found to be 
localized in proliferating epithelia at the base of the crypts in the intestinal tract.  
FIZZ2/RELMβ is also present in rapidly dividing epithelia by demonstrating a marked increase 
in intestinal tumors compared with control epithelia (Steppan et al., 2001b). RELM is also 
produced in adipose tissue (Steppan et al.; 2001b).  
 
The third homolog, FIZZ3, is known as resistin or adipocyte-specific secretory factor and is 
identical to the fat specific homolog (Rajala et al., 2002). Steppan et al., demonstrated that 
resistin is increased in type II diabetes and is a potential link between obesity and insulin 
resistance (Steppan et al., 2001a). Notably, injection of recombinant resistin into mice reduces 
glucose tolerance and insulin action, whereas neutralization with anti-resistin antibodies 
improves insulin action.  
 
1.4.3.2 Functions 
The potential function of resistin or its homologs requires further, study (Flier, 2001b). As fat 
cells (adipocytes) store more fat molecules and enlarge, they release several products that can 
modify the body’s sensitivity to insulin. Free fatty acids and TNF-α cause insulin resistance, 
and leptin, which regulate energy balance is implicated in development of insulin sensitivity.  
 
Initial studies have demonstrated that obesity induced by a high-fat diet, mutation of the leptin 
gene (ob/ob mice), or mutation in the leptin receptor gene (db/db mice) is associated with 
increased circulating resistin concentration. Resistin increases blood glucose and insulin 
concentration in mice.  It also impairs hypoglycemic response to insulin infusion. In addition, 
anti-resistin antibodies decrease blood glucose and improve insulin sensitivity in obese mice 
(Ukkola, 2002). Resistin suppresses insulin-stimulated glucose uptake in cultured 3T3-L1 
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adipocytes, and this effect is prevented by anti-resistin antibodies. These data suggest that 
resistin provokes insulin resistance and that hyper-resistinemia contributes to impaired insulin 
sensitivity in obese rodents (Shuldiner et al., 2001); (Way et al., 2001b); (Moore et al., 2001b) 
and (Lay et al., 2001).  The latter group also observed lower resistin mRNA in adipose tissue in 
a model of mouse obesity viz., diet-induced obesity.  Likewise, they observed hyper-
insulinemia, hyperglycemia, hypertriglyceridemia, and hypertension in a rat model of obesity.  
 
The physiologic role of resistin in humans remains unclear. Given the incomplete homology 
between human and mouse resistin and the absence of one of the three resistin isoforms, 
resistin in humans may have a different physiologic role to that in mice.  
 
There is no correlation between body weight, adiposity, insulin resistance and resistin mRNA 
concentration. Thus, the role of resistin and other members of the FIZZ/RELM family in 
humans remains to be established. These proteins may be involved in the regulation of cell 
proliferation and differentiation. Given the production of FIZZ1/RELMα and of resistin in 
inflammatory cells it is a  possibility that their involvement in chronic inflammatory reactions 
may be associated with obesity (Gomez-Ambrosi and Fruhbeck, 2001).  
 
1.4.3.3 Resistin in pregnancy 
Resistin is significantly higher in normal pregnant compared to non-pregnant women. Pre-
eclamptic women have significantly lower resistin levels than their normotensive counterparts 
at similar gestational ages (Cortelazzi et al., 2007).  Elevated levels of serum resistin was noted 
in the third trimester of normotensive pregnancy compared to non-pregnant healthy females. In 
comparison, resistin levels were lower in pre-eclamptics matched for gestational age and BMI 
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(Chen et al., 2005). It is plausible to hypothesise that a possible link exists between resistin and 
placental mass. This study will interrogate this correlation. 
 
Figure 1.7: Structure of resistin: An illustration of resistin assembled as a trimer, the less stable 
but more biologically active state of the hormone modified from Amity Tung, Molecules of the 
Quarter UCLA Department of Chemistry and Biochemistry 
 
 
1.4.4 Tumour necrosis factor (TNF) 
TNF is involved in systemic inflammation and is a member of a group of cytokines/adipokines 
that stimulate the acute phase reaction. Although it is primarily produced by macrophages, it is 
also produced by endothelial cells and adipocytes (Locksley et al., 2001). 
 
The TNF gene is located on chromosome 6p21.3, spans 3 kilobases and contains 4 exons. The 
last exon codes for more than 80% of the secreted protein (Nedwin et al., 1985). TNF is 
primarily produced as a 212-amino acid-long type II transmembrane protein arranged in stable 
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homotrimers (Kriegler et al., 1988, Tang et al., 1996). Emanating from this membrane-
integrated form the soluble homotrimeric cytokine (sTNF) is released via a proteolytic cleavage 
via TNF alpha converting enzyme (TACE), also called ADAM17;  (Black et al., 1997). The 
soluble 51 kDa trimeric sTNF tends to dissociate at concentrations below the nanomolar range, 
thereby losing its bioactivity (Black et al., 1997). 
 
1.4.4.1 Tumour necrosis factor receptors 
TNF can bind to two receptors, TNF receptor type 1 (TNF-R1) and TNF receptor type 2 (TNF-
R2). TNF-R1 is expressed in most tissues, and can be fully activated by both the membrane-
bound and soluble trimeric forms of TNF, whereas TNF-R2 is found only in cells of the 
immune system, and responds to the membrane-bound form of the TNF homotrimer (Guoqing 
and Goeddel, 2002). 
 
Upon contact with their ligand, TNF receptors also form trimers, their tips fitting into the 
grooves formed between TNF monomers. This binding causes a conformational change to 
occur in the receptor, leading to the dissociation of the inhibitory protein SODD from the 
intracellular death domain. This dissociation enables the adaptor protein TRADD to bind to the 
death domain, serving as a platform for subsequent protein binding. Following TRADD 
binding, three pathways can be initiated (Guoqing and Goeddel, 2002, Wajant et al., 2003).  
 Activation of NF-κB:  NF-κB is a transcription factor that translocates to the nucleus 
and mediates the transcription of a vast array of proteins involved in cell survival and 
proliferation, inflammatory response and anti-apoptotic factors. 
 Activation of the mitogen activated protein kinase (MAPK) pathways: Of the three 
major MAPK cascades, TNF induces a strong activation of the stress-related Jun N-
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terminal kinase (JNK) group. The JNK pathway is involved in cell differentiation, 
proliferation, and is generally pro-apoptotic. 
 Induction of death signaling: Like all death-domain-containing members of the TNFR 
superfamily, TNF-R1 is involved in death signaling (Gaur and Aggarwal, 2003). 
However, TNF-induced cell death plays only a minor role compared to its 
overwhelming functions in the inflammatory process. 
 
 
Figure 1.8: This is a model of the Tumor Necrosis Factor Receptor1 (TNFR1) for Tumor 
Necrosis Factor Alpha (TNF-α). TNF-α is shown bound to the extracellular ligand-binding 
domain of the transmembrane TNFR1 – modified from: php.med.unsw.edu.au 
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1.4.4.2 TNF in pregnancy 
In normal pregnancy, at physiologic concentrations, TNF-α acts as a regulatory apoptotic agent 
that limits the invasive abilities of extravillous trophoblastic cells necessary for appropriate 
placental anchorage and blood flow toward the intervillous space (Fukushima et al., 2003). 
TNF-α has been shown to directly increase transcription of the vasoconstrictor peptide 
endothelin (ET), ET-1 (Marsden and Brenner, 1992, Roberts et al., 2006). Because endothelial 
damage is a known stimulus for ET-1 synthesis, increases in the production of ET-1 and 
activation of ETA receptors have been proposed to participate in the pathophysiology of 
hypertension during pre-eclampsia (Roberts et al., 1991, Taylor and Roberts, 1999).
 
Furthermore, plasma concentrations of ET (ET-1) are increased two- to threefold in patients 
with pre-eclampsia compared to normal pregnant women. This increase occurs late in the 
disease process, suggesting that it may play a role in the progression rather than the initiation of 
pre-eclampsia (Roberts et al., 1991, TAYLOR et al., 1990, Taylor and Roberts, 1999, Nova et 
al., 1991, Wang et al., 1994). 
 
The role of certain adipose derived proteins has been implicated in enhancing pro-inflammatory 
responses.  In contrast to HIV infection, pre-eclampsia is associated with immune hyper-
reactivity.  HIV infection is also associated with muscle wasting, hence the levels of these 
hormones may be dysregulated and requires investigation (Matarese et al., 2005, Lago et al., 
2007, Garg, 2004). Additionally, this dysregulation may serve as a predictor test for the 
predisposition to the development of pre-eclampsia. 
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1.5 HIV IN SA 
Sub-Saharan Africa carries the majority of the AIDS disease burden when considering the HIV 
pandemic (UNAIDS, 2008, Ramjee et al., 2012). South Africa has more than six million people 
infected with HIV/AIDS (UNAIDS, 2013) Geographic variations of the epidemic in South 
Africa reflect a provincial difference with KwaZulu-Natal having the highest incidence.  It is 
also  considered the epicentre of this global pandemic (Ramjee et al., 2012).  
 
In South Africa, the national HIV prevalence amongst women has dropped from 30.2% to 
29.1% (Udjo, 2006). Notably, the epidemic has devastating consequences on women of 
reproductive age 15 - 24 y (Moodley and Moodley, 2005). Approximately 30% of South 
African parturients are co-infected with HIV (Kalumba et al., 2013). The latest report of the 
National Committee on Confidential Enquiries into Maternal Deaths in South Africa indicates 
that HIV/AIDS contributes to approximately 41% of all maternal deaths (Dpt of Health South 
Africa, 2012).  As expected, KZN has a  40%  infection rate in pregnant women (Kalumba et 
al., 2013).   
 
1.5.1 Role of HIV in pre-eclampsia 
The change in body fat distribution is a common finding in individuals with HIV infection, 
being treated with antiretrovirals. This condition has many similarities with rare, congenital and 
acquired lipodystrophies. This is associated with depletion of subcutaneous fat, increased 
triglycerides and profound insulin resistance (Addy et al., 2003).  Recent studies have shown 
that these patients have marked changes in circulating levels of adipocyte secreted hormones, 
including leptin and adiponectin. This may contribute to the noted metabolic abnormalities 
(Nagy et al., 2003, Chaparro et al., 2005). 
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In HIV lipodystrophies, adiponectin levels are significantly lower in patients with fat 
redistribution and correlate inversely with serum triglycerides and insulin resistance, with 
levels being lowest in individuals with peripheral lipoatrophy and central lipohypertrophy 
(Chaparro et al., 2005, Verkauskiene et al., 2006, Khan et al., 2006). 
 
A significant increase in pre-eclampsia and fetal death in HIV-infected pregnant women on 
highly active antiretroviral therapy (HAART)  have been reported (Suy et al., 2006). Pregnant 
women attending the Hospital Clinic in Barcelona, Spain were catechised to determine an 
association between pre-eclampsia and/or fetal death and HAART.  During January 2001 - 
August 2003, 8 295 women delivered babies of whom 82 (0.9%) were HIV infected.  Overall, 
237 (2.9%) of the HIV-uninfected women developed pre-eclampsia and 40 (0.5%) was 
associated with fetal death. Alarmingly, the HIV-infected women had a much higher rate of 
pre-eclampsia (11%) development with a significantly higher incidence of fetal death (6.1%) 
(Suy et al., 2006). 
 
Of interest is the mirrored effect of the inflammatory adipokines on HIV susceptibility. HIV-1 
seropositive women with clinical conditions of pro-inflammatory mediator production in the 
placenta were found to be at increased risk of HIV-1 transmission to their fetuses (Parry et al., 
2006). Moreover, inflammatory mediators such as TNF-α produced locally by the placenta 
augment HIV-1 infection and replication (Vigano et al., 1998, Hamamoto et al., 1990). 
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1.5.2 Role of HIV in adipokine formation 
The advent of highly active anti-retroviral therapy (HAART) was a turning point in the history 
of the acquired immune deficiency syndrome. Side effects of HAART therapy include  insulin 
resistance, metabolic abnormalities, and changes in body shape (Carr et al., 1998a). 
 
HIV associated lipodystrophy syndrome (HALS) is one the first and commonest secondary 
effects noted. HALS characteristically occurs as peripheral lipoatrophy of subcutaneous 
adipose tissue (in the face, limbs and buttocks), visceral fat accumulation, and lipomatosis, 
especially in the dorsocervical area (“buffalo hump”) (Giralt et al., 2011).In obesity, secretion 
of peptide hormones such as leptin and adiponectin by adipose tissue is disturbed, a disruption 
that has been associated with insulin resistance, metabolic syndrome, and cardiovascular 
diseases (Kadowaki et al., 2007); Guzik et al., 2006). 
 
Evidence suggests that adipokines play a role in metabolism, energy homeostasis, weight 
regulation, and many other biological processes (Carr et al., 2004).Studies on mice show that 
adiponectin decreases liver and muscle triglycerides by up-regulating the expression of 
molecules involved in fatty acid oxidation and muscle energy expenditure (Fruebis et al., 
2001).  Levels of adiponectin have been found to be lowered in obesity, diabetes, non-alcoholic 
liver disease and some subsets of lipodystrophy including HALS patients – Addy et al., 2003;  
Kadowaki, 2005). 
 
As obesity and HIV have become critical disorders of the South African population and pre-
eclampsia remains one of the instrumental causes of maternal mortality it has been decided to 
design a study to address the impact of all three on one another. 
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1.6 AIMS /OBJECTIVES OF STUDY 
1.6.1 Primary objectives 
1. Compare serum levels of adiponectin, leptin, resistin and TNF-α (adiponectin / leptin / 
resistin / TNF-α) in the pregnant compared to the non-pregnant Black population in the 
maternal serum. 
2. Compare serum levels of adiponectin / leptin / resistin / TNF-α in HIV+ve parturients as 
compared to HIV-ve parturients in the maternal serum. 
3. Compare serum levels of adiponectin / leptin / resistin / TNF-α in patients with early 
onset as compared to late onset pre-eclampsia in the maternal serum. 
4. Compare serum levels of adiponectin / leptin / resistin / TNF-α in patients with 
normotensive pregnancy compared to late onset pre-eclampsia in the maternal serum.  
5. Compare serum levels of adiponectin / leptin / resistin / TNF-α in patients with pre-
eclampsia and HIV as compared to patients with pre-eclampsia but without HIV in the 
maternal serum. 
 
1.6.2 Secondary objectives 
1. Compare the serum levels of adiponectin / leptin / resistin / TNF-α in HIV+ve pregnant 
women with a CD4 count above 350 in the maternal serum. 
2. Compare the levels of adiponectin / leptin / resistin / TNF-α in HIV+ve pregnant 
women with a CD4 count below 350 in the maternal serum. 
3. Compare the levels of adiponectin / leptin / resistin / TNF-α in pregnant HIV+ve 
women on ARVS and those not on ARVs in the maternal serum. 
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1.6.3 Hypotheses 
1. The levels of adiponectin / leptin / resistin / TNF-α differ in the pregnant and non-pregnant 
populations. 
2. The levels of adiponectin / leptin / resistin / TNF-α differ in women who develop early 
onset pre-eclampsia as compared to women who develop late onset pre-eclampsia. 
3. The levels of adiponectin/ leptin /resistin / TNF-α in pre-eclamptics also differ according to 
HIV status. 
4. The difference in levels of adiponectin/ leptin / resistin / TNF-α in women who develop 
early onset pre-eclampsia as compared to women who develop late onset pre-eclampsia are 
also altered by the HIV status of the patients.  
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1. STUDY SITE, ETHICS APPROVAL AND INFORMED CONSENT 
 
This prospective study was approved by the Institutional Postgraduate Committee (Addendum 
1) and was conducted at RK Khan Hospital in KwaZulu-Natal, South Africa. Ethical approval 
was obtained from the Biomedical Research Ethics Committee (BREC 256 /12 – Addendum 2).  
Permission to perform the study at RK Khan Hospital was obtained from the Hospital Manager 
(Addendum 3). The study was conducted during the period of 1
st
 August 2012 – 30
th
 April 
2014.  Written informed consent was obtained from each participant in both English and Zulu 
(Addendum 4). 
 
2.2. STUDY POPULATION 
 
Participants were recruited at the Obstetric Unit (antenatal ward) of RK Khan Hospital by the 
primary investigator, a qualified obstetrician/gynaecologist, during the antepartum period.  
International standard definitions of pre-eclampsia were employed during the selection process 
(National High Blood Pressure Education Program Working Group on High Blood Pressure in, 
2000). All participants were managed by standard of care policies in accordance with the 
National Department of Health, South Africa. Non pregnant patients were recruited from the 
Gynaecology Unit (contraceptive clinic) at RK Khan Hospital. All non-pregnant participants 
(more than 6 weeks post-partum) in good clinical health and are between the ages of 18 – 45 y 
were eligible for participation. 
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Participants were recruited into one of three groups:  
 non pregnant normotensive population (n = 119),  
 pregnant normotensive population (n = 118) and  
 pre-eclamptics (n = 91).   
 
A schematic outline of the three study groups are shown in Figure 2.1. Each study group was 
further, sub-divided according to HIV status. HIV positive participants were further, stratified 
by their CD4 count and ARV usage.  
 
In addition, all pre-eclamptic patients were further, classified as either early or late onset 
disease. Early onset pre-eclampsia (EOPE) was defined as onset of pre-eclampsia after 20 
weeks of gestation, but prior to 34 weeks completed gestation. Late onset pre-eclampsia 



























Figure 2.1: Schematic diagram of pregnant and non-pregnant cohorts. Each cohort was 
stratified according to HIV status 
 
2.2.1. Inclusion Criteria 
All Black South African patients over 18 years of age were eligible for participation in the 
study. HIV status and CD4 count were examined prior to entry into the study. Patients were 
categorised into non-pregnant normotensive, pregnant normotensive and pre-eclamptic cohorts. 
HIV –ve = 60 
 




N = 118 
 
Pre-eclamptics 
N = 90 
 
HIV –ve = 69 
 
HIV +ve = 49 
HIV –ve = 58 
 
HIV +ve = 32 
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The pre-eclamptic group was further, sub-categorised according to gestational age, i.e., ≥ 34 
weeks gestation. The pregnant population was further, compared to a non-pregnant, healthy 
reproductive age female population according to HIV status and CD4 count. Non pregnant 
participants were eligible for entry provided they were between 18 – 45 y. Their HIV status had 
to be known. 
 
2.2.2. Exclusion Criteria 
Exhaustive exclusion criteria were used in an effort to maintain a homogenous study 
population. The following patients were excluded from the study: 
 
a) Patient’s with chronic hypertension 
b) Non-Black African patients 
c) Gestational diabetics 
d) Chronic diabetics 
e) Patients with unknown HIV status  
f) Unbooked patients 
g) Patients with chorioamnionitis 
h) Polycystic ovarian syndrome patients 
i) Patients with thyroid disorders 
j) Patients with chronic renal disease 
k) Patients with cardiac failure 
l) Patients with connective tissue disease / antiphospholipid syndrome 
m) Patients with abruption placentae 
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2.3. SAMPLE COLLECTION 
 
2.3.1. Patient Demographics 
Participant demographics were collated by the researcher into a pre-designed data sheet 
(Appendix 2.4) during the antepartum period. These included maternal age, residential area, 
smoking and drug habits, HIV status and CD4 counts, antiretroviral usage (3-drug versus 
PMTCT regimens), parity, gravidity, previous reasons for miscarriage, blood pressures at 
confirmation of pre-eclampsia, height, weight, body mass index (BMI), mid upper arm 
circumference (MUAC), triceps skin fold thickness, presence and degree of oedema, urine 
dipstick findings at time of diagnosis of pre-eclampsia. Indications and mode of delivery as 
well as associated complications were noted. Fetal ultrasound abnormalities, neonatal outcomes 
in terms of APGARS, baby weight, placental shape and weight and appearance and umbilical 
cord length were recorded. 
 
The Body Mass Index (BMI) was calculated by dividing the body weight (kg) by the height 
squared (m) i.e., 
 
BMI = weight 




Obesity was defined as a BMI of at least 30 kg/m
2 
(Kafulafula and Moodley, 2001). 
Additionally, the mid upper arm circumference was taken with a measuring tape at the 
midpoint between the olecranon and the acromion process of the right arm. The triceps skin 
fold thickness was measured with the participant standing upright with arms loosely hanging at 
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her sides. The subcutaneous tissue and skin of the midpoint of the posterior part of the right 
arm was measured with a skin fold caliper. The mid-arm muscle circumference was calculated 
by using the following formula:  
 
Mid-arm muscle circumference = mid-arm circumference – [3.14 X triceps skin fold thickness] 
(Huang et al., 2001).  
 
2.3.2. Blood collection 
Peripheral venous blood was collected during the antepartum period as pre-eclampsia rapidly 
resolves post-partum. Four vials each containing 10 ml of blood were collected per patient in 
EDTA anti-coagulant tubes and plain vials, after application of a tourniquet above the ante-
cubital fossa. HIV tests and CD4 counts are offered as part of the standard of care in the ante-
natal clinic. Only those patients agreeing to HIV-testing were offered placement in the study.  
 
Each patient data analysis form had a hospital identification number. In an effort to maintain 
participant anonymity, each patient was allocated a study identification number. The study 
identification number was written onto specimen collection vials. Blood samples were then 
transported in a cooler box within two hours of collection to the Optics and Imaging Centre, 
Doris Duke Medical Research Institute at the Nelson R. Mandela School of Medicine to be 





In September 2014, these specimens were subsequently transferred by an international courier 
at -80
o
C to the Staten Serum Institute, Copenhagen, Denmark. Conformance to international 
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standards of specimen export and transportation were strictly adhered to (Addendum -2.5). The 
experimental procedures were performed under combined supervision of the primary 
investigator and collaborators at the Statens Serum Institut.  
 
2.4. ENZYME-LINKED IMMUNOSORBENT ASSAY DETERMINATION OF SERUM 
ADIPONECTIN AND TNF- α 
 
2.4.1. Principle of serum adiponectin and TNF-α detection 
This technique was first described by Engvall and Perlmann in 1972 and once more in 1982 by 
Gaastra (Engvall and Perlmann, 1972, Gaastra, 1984). It has been described as the double 
antibody sandwich technique. Antibodies against the antigen to be measured are adsorbed to a 
solid phase support and antigen is then added to the adsorbed antibodies. Thereafter a second 
enzyme labelled antibody is added. The addition of an enzyme substrate allows measurement as 
the degree of colour is proportional to the original bound antigen-antibody (Gaastra, 1984). 
 
The ELISA testing was performed using the DuoSet ELISA Development System and 
instructions followed from the human Adiponectin (Acrp30 catalogue: DY 1065) 
 Capture antibody – 360 µg/ml of mouse anti-human adiponectin was reconstituted with 
1.0 ml of PBS and 720 µg/ml of mouse anti-human TNF-α is reconstituted in 1.0 ml of 
PBS. 
 Detection antibody – 360 µg/ml of biotinylated mouse anti-human adiponectin was 
reconstituted with 1.0 ml of reagent diluent and 90 µg/ml of biotinylated goat anti-
human TNF-α is reconstituted with 1.0 ml of reagent diluent) 
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 Standard – 70 ng/ml of recombinant human adiponectin was reconstituted with 0.5 ml 
of reagent diluent. The standard was allowed to incubate for a minimum of 15 minutes 
with gentle agitation prior to further, dilutions and 370 ng/ml of recombinant human 
TNF-α is reconstituted with 0.5 ml of reagent diluent and gently agitated for a minimum 
of 15 minutes. 
 Streptavidin-HRP – 1.0 ml of streptavidin was conjugated to horseradish –peroxidase. 
 
The adiponectin, and TNF-α assay utilizes either a mouse anti-human adiponectin or TNFα, 
antibody as appropriate for immobilization on the microtiter wells. Biotinylated mouse anti-
human adiponectin antibody along with streptavidin conjugated to horseradish peroxidase 
(HRP) is added to enable detection of the antigen through colour change. This is followed with 
the addition of a reagent diluent (200µl) and incubated as directed by the kit being used. Post 
washing a HRP substrate, tetra-methylbenzidine (TMB), was then added with the resultant 
development of a blue colour (Figure 2.2). Progress of colour development was stopped by the 
addition of Stop Solution – this changed the colour to yellow. The concentration of adiponectin 
and TNF-α was directly proportional to the colour intensity of the test sample. Absorbance was 
read spectrophotometrically at 450 nm (Systems). 
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Figure 2.2: Schematic diagram illustrating ELISA procedure – adapted from (Ramawi, 2012) 
 
2.4.2. Procedure for adiponectin and TNF-α detection by ELISA (RnD Systems) 
Table 2.1 Table outlining the ELISA procedure for the determination of serum adiponectin and 
TNF-α 
Step Process  Method Time 
1 diluted samples  100 µl of sample in reagent diluent  2 h (1 h preparation + 1 
h incubation) 
2 wash wells Wash buffer  40 min 
3 detection antibody 100 µl detection Ab diluted with 
reagent diluent 
40 min 
4 wash wells Wash buffer x3 
5  Streptavidin-HRP 100 µl of Streptavidin-HRP  40 min 
6 stop solution  50 µl stop solution  20 min 
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2.4.3. Detection limits and co-efficient of variation (CV) 
The coefficient of variation (CV) was defined as the ratio of the standard deviation σ to the 
mean µ: 
 
Cv =  σ 
 µ 
 
 CV shows the extent of variability in relation to mean of the population. 
 
The detection limit for the adiponectin assay was 1.43 µg/l; coefficient of variation (CV) within 
and between assays was < 4.58%.  For the TNF assay the detection limit was 1.39 µg/l; CV 
within and between assay was < 3.02%. 
 
2.5. DETERMINATION OF SERUM LEPTIN AND RESISTIN BY BIOPLEX 
IMMUNOASSAY 
 
2.5.1. Principle of serum leptin and resistin detection by Bioplex assays 
Bioplex cytokine assays are multiplex bead assays designed to quantify multiple cytokines in 
diverse matrices, including serum, plasma and tissue samples. This multiplexing allows 
quantification of multiple cytokines in a single well. The advantage of this method is that it 
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The principles behind the procedure are: 
1. Fluorescently dyed beads are present to which biomolecules are bound. 
2. A flow cytometer with 2 lasers and associated optics are needed to measure the 
biochemical reactions that occur on the surface of the beads. 
3. A high speed digital signal processor is used to manage the fluorescent output. 
 
Each colour-coded bead is conjugated to a specific reactant, which is specific for a target 
molecule. The assay is designed in a capture sandwich immunoassay format. 
In this study a specific antibody is directed against the cytokine of interest and is covalently 
coupled to colour coded beads which reacts with the sample containing an unknown amount of 
the cytokine. 
 
As in other multiplex assays reaction mixture is subsequently detected by the addition of 
Streptavidin-phycoerythrin (SA-PE). This binds to the biotinylated detection antibodies. The 
constituents of each well are drawn up into a flow based suspension array system which 
identifies and quantifies each specific reaction based on bead colour and fluorescence.  
 
The magnitude of the reaction is then measured using fluorescently labelled reporter molecules 
associated with each target protein. Unknown cytokine concentrations of the sample are 
calculated from a standard curve that has been derived from a recombinant cytokine standard. 
These standard curves are provided by the multiplex assay used – in this case the Bioplex Pro 
assay kit was used (BIORAD, 2014). 
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2.5.2 Preparation and procedure: 
The plate layout was planned ahead of the experiment. Approximately 30 minutes were 
required to bring the assay buffer, wash buffer and sample diluent to room temperature. The 
vacuum manifold was set to -1 to -3 mmHg for the filter plate. A single vial of standard was 
reconstituted in 500 µl of diluent similar to the final sample type (matrix). This was vortexed 
for 5 seconds and thereafter incubated on ice for 30 minutes. 
 
A fourfold standard dilution series and blank were prepared. The standard dilutions were 
vortexed for 5 seconds in between liquid transfers. The serum samples were prepared in 1:4 
dilution with the sample diluent. The coupled beads were vortexed for 30 seconds and were 
diluted to 1X assay buffer – this is light sensitive hence it was performed away from light. 
 
The plates were subsequently washed three times with 100 µl wash buffer. The diluted 1X SA-
PE was vortexed and 50 µl was added to each well and then vortexed for 5 seconds and 
incubated on ice for 30 minutes. The plate was then washed three times with 100 µl wash 
buffer. The beads were then resuspended in 125 µl assay buffer. The plate was covered and 
centrifuged at 850 rpm for 30 seconds. The sealing tape was then removed and the plate was 
read using  Bioplex Manager Software (BIORAD, 2014). 
 
A series of known concentrations of an analyte was used to construct a plot of signal intensity 
vs concentration. The plot was mathematically modelled to derive an equation that may be used 
to predict the concentration of the unknown samples. Both, the type of mathematical model as 
well as the fit of the model were considered as they have a direct effect on the accuracy of the 
results. Curve fitting was a critical component of immunoassay performance.  




Figure 2.3:  Diagram of Bioplex test procedure as adapted with permission from Biorad 
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2.5.3 Linear regression 
This is the simplest method for determining concentration from a standard curve. The plot was 
constructed on concentration vs response. This method has been used traditionally to quantitate 
results of ELISA and other immunoassays (Wild, 2005). 
 
 2.5.4 Logistic regression: 
Immunoassay data may also be used in a non-linear regression routine. The log of the 
concentration was plotted on the X-axis  vs the response (fluorescence intensity) plotted on the 

















log of the concentration 
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2.6 STATISTICAL ANALYSIS 
 
SPSS version 21 was used to analyse the data. A p value < 0.05 was considered as statistically 
significant. Demographic variables were summarised using mean, standard deviation and range 
for continuous variables, and frequency tables for categorical variables. Outcome variables 
were extremely non-normally distributed, therefore non-parametric tests were used to compare 
median levels between groups. Two independent groups were compared using Mann-Whitney 
























3.1 STUDY POPULATION 
A total of 328 women attending RK Khan Hospital, a regional and district hospital in 
Chatsworth, a suburb in the eThekwini health district, KwaZulu-Natal were studied. Based on 
inclusion and exclusion criteria (2.2.1 and 2.2.2), women were recruited into two groups ie., 
non-pregnant (n = 120; 36.58%) and pregnant  group (n = 208; 63.41%). Pregnant women were 
further, categorised into the normotensive pregnant (n = 118; 35.97%) and the pre-eclamptic (n 
= 90; 27.43%) groups (Figure 3.1). 
 
The pregnant cohort was also sub-stratified in accordance with their HIV status.  Of the 118 
normotensive pregnant women, 49 (41.52%) were HIV positive whilst 69 (58.47%) were HIV 
negative. Likewise the pre-eclamptic women were also stratified according to their HIV status 




 - 53 - 
 















Normotensive  pregnant 
n = 118 
Pregnant cohort 
n = 208 
Pre-eclamptic 
n = 90 
HIV+ 
n = 32 
HIV-  
n = 58 
HIV+ 
n = 49 
HIV- 
n = 69 
HIV-
ve 




N = 60 
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3.2 DEMOGRAPHIC AND CLINICAL DATA OF STUDY POPULATION  
 
3.2.1 Maternal Age  
Age was not normally distributed amongst the study groups.  Additionally, both log and square 
root transformations of the age data failed to achieve normality.  A Kruskal-Wallis H test was 
then used to analyse mean ranks of age (raw data) across the study groups. 
 
Patient age ranged between 18 - 45 y across all the study population (Table 3.1; Figure 3.3). 
The mean age of study participants in the non- pregnant group was 27.75 ± 7.8 y (range: 21 – 
37 y) compared to 27.30 ± 5.7 y (range: 18 - 41 y) in the normotensive group.  The mean age of 
participants in the EOPE group was 26.38 ± 6.1 y (range: 18 - 31 y) compared to 26.62 ± 7.5 y 
(range: 19 – 38 y) in the LOPE group. Upon initial inspection there appeared to be no 
significant difference in and between study groups. However, there was a statistically 
significant difference in the distribution of age across the categories according to HIV status (p 
< 0.00). Patients were older in the HIV+ve group as compared to the HIV-ve group. 
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Figure 3.2: Boxplot of maternal age (y) across the study population  
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Figure 3.3:  Boxplot illustrating maternal age (y) across the HIV positive groups 
 
A Kruskal-Wallis H test showed that there was a statistically significant difference in age 
between the different groups, [χ
2
(3) = 69.723; p < 0.000], with a mean rank age score of 217.28 
for non-pregnant, 125.27 for normotensive pregnant, 161.32 for EOPE and 121.49 for the 
LOPE groups.  The effect size (η
2




Pairwise Mann Whitney U comparisons were made between pairs of groups to identify which 
groups were different.  A Bonferroni post hoc analyses (adjusted p < 0.008) revealed that there 
were statistically significant differences between median ages of the non-pregnant group versus 
normotensive pregnant, EOPE and LOPE groups respectively (U: 3035.5; p < 0.000; U:1175;  
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p < 0.001; U:1267; p < 0.000).  There were no significant differences between normotensive 
pregnant versus EOPE and LOPE group combinations. 
  
When comparing the HIV positive versus the HIV negative participants, the Levene’s test of 
equal variances using a 2 tailed T-test showed a statistically significant difference in age 
between the 2 groups (p < 0.000). 
 
Furthermore, when considering the effect of HIV, post Kruskal-Wallis H test and Bonferroni 
post hoc analysis, a statistically significant difference between the different groups, [(χ
2
(7) = 
85.486); p < 0.000], was found across the categories (Table 3.1; Figure 3.5). 
 
Figure 3.4: Boxplot illustrating maternal age (y) based on HIV status 
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3.2.2 Blood Pressure 
3.2.2.1 Systolic blood pressure 
The mean systolic blood pressure for non-pregnant participants was 133 ± 26.47 mmHg versus 
117.7 ± 9.31 mmHg of the normotensive pregnant participants. The mean systolic blood 
pressure for EOPE was 168 8.07 mmHg compared to 161.08 ± 22.55 mmHg in the LOPE 
group.  A detailed statistical assessment of systolic blood pressure across the study groups is 
outlined in Table 3.3 and Figure 3.6 respectively. 
  
There was a statistically significant difference between groups as determined by one-way 
ANOVA (F(3,322) = 308.790, p = 0.000). A Fisher’s least significant difference (LSD) post-
hoc test revealed that the systolic blood pressure was statistically significantly lower in the non-
pregnant group (118.903 ± 10.907 mmHg, p = 0.000) compared to the early onset (168.654 ± 
15.552 mmHg, p = 0.000) and late onset pre-eclamptic groups (163.38 ± 16.787 mmHg; Figure 
3.6). There were no statistically significant differences between the non-pregnant and 
normotensive groups (p > 0.05). There were no statistically significant difference of the systolic 
blood pressure between the EOPE and LOPE groups (p > 0.050).  
 
However, of interest is the fact that when Levene’s test where equal variances was not assumed 
and a 2 tailed T-test was then performed, a statistically significant difference of p = 0.000 was 
found between all groups. 
 
After  considering the effect of HIV, the Kruskal-Wallis H test and Bonferroni post hoc 
analysis, demonstrated a statistically significant difference between the systolic blood pressure 
across different groups,[(χ
2
(7) = 192.040); p = 0.000], was demonstrated (Figure 3.7). 
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Figure 3.5: Boxplot showing the systolic blood pressure (mmHg) across groups 
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 3.2.2.2 Diastolic blood pressure 
The mean diastolic blood pressure for non-pregnant participants was 77.25 ± 15.17 mmHg (p < 
0.003) compared to 73.34 mmHg normotensive pregnant group. The mean diastolic blood 
pressure was 109.13 ± 14.567 mmHg compared to 96.54 ± 7.6 mmHg in the EOPE and LOPE 
groups respectively. 
 
There was a statistically significant difference in the mean ± standard deviation of the diastolic 
blood pressure between groups as determined by one-way ANOVA [F(3,322) = 146.320, p = 
0.000]. A Fisher’s least significant difference post-hoc test revealed that the mean diastolic 
blood pressure was statistically significantly lower in the non-pregnant group (72.34 ± 11.247 
mmHg) compared to the EOPE (104.91 ± 14.567 mmHg,) and the LOPE groups (100.97 ± 
7.655 mmHg)  (p = 0.000; Figure 3.8).  There were no statistically significant differences 
between the non-pregnant and normotensive groups (p = 0.607). Likewise, there were no 
statistically significant differences between the EOPE and LOPE groups (p = 0.107). 
 
Only when, the Levene’s test compared the pre-eclamptic group as a whole to the normotensive 
group (irrespective of equal variance or not), the 2 tailed T-test showed a statistical significance 
of p = 0.000 (Table 3.1). 
 
When considering the effect of HIV, the Kruskal-Wallis H test and Bonferroni post hoc 
analysis demostrated a statistically significant difference between the different groups, [(χ2(7) 
= 170.898); p = 0.000] (Figure 3.9). 
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Figure 3.7: Boxplot of diastolic blood pressure (mmHg) across study  groups 
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3.2.3 Gestational Age 
The mean gestational age of normotensive pregnant participants was 38.98 ± 1.5 weeks. The 
mean gestational age of participants with EOPE was 32 ± 3.8 weeks versus 36.92 ± 1.847 
weeks in the LOPE groups. 
 
Gestational age was not normally distributed but there was homogeneity of variance amongst 
groups. Therefore a Kruskal Wallis omnibus test was performed to check for a difference 
amongst the groups.   The Kruskal-Wallis H test showed a statistically significant difference in 
gestational age between the different groups, [(χ
2
(2) = 83.196); p = 0.000], with a mean rank 
gestational age score of 131.50 for normotensive, 28.98 for EOPE and 87.33 for the LOPE 
groups.  The effect size (η
2
) of the difference in mean ranks was 40.6% [calculated as χ
2
/(n-1) = 
83.196 divided by 206-1] demonstrating the effect of the mean rank on gestational age. 
 
Mann Whitney U tests performed indicated that the normotensive groups was significantly 
higher than both the EOPE (U=190.50; p < 0.000) and LOPE groups (U = 1654.00; p = 0.000). 
The pregnancies EOPE groups terminated at an earlier gestation than the LOPE groups (U = 
205.0; p = 0.000). 
 
Furthermore, the Levene's test followed by a 2 tailed T-test compared the pre-eclamptic group 
as a whole (EOPE + LOPE) to the normotensive group (irrespective of equal variance or not), a 
statistical significance of p = 0.000 was demonstrated. In addition, when the Levene's test 
compared the EOPE and LOPE groups (irrespective of equal variances or not) and a 2 tailed T-
test then performed, a statistically significant difference of p = 0.000 was noted (Table 3.1). 
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The study demonstrated there was no statistically significant difference in the distribution of 
gestational age across the pregnant categories according to HIV status (Figure 3.10). 
 
 
Figure 3.9: Boxplot of gestational age (weeks) across pregnant groups 
 
 
3.2.4 Indications for delivery 
Within the pregnant cohort (normotensive pregnant + pre-eclamptic); 65.9% of deliveries were 
in fetal interest as compared to maternal indications. The Pearson Chi-square test showed a 
statistically significant difference between the groups of p = 0.000. Pregnant patients (45.4%) 
had elective caesarean section compared to the 27.4% requiring emergency caesarean section.  
 - 66 - 
Over four percent (4.6%) required induction of labour whilst 22.6% had a spontaneous normal 
vaginal delivery. 
 
3.2.5 Clinical complications in the pre-eclampsia groups 
Clinical complications included one case of abruption placentae, 9 cases of eclampsia, 5 cases 
of imminent eclampsia and 12 cases of severe pre-eclampsia. Moreover, there were 6 cases of 
stillbirths. In the EOPE group, there were 5 patients that developed eclampsia and one case of 
abruption placentae. 
 
3.2.6 Birth weights across study groups 
Babies of normotensive participants had a mean birth weight of 3.237 ± 0.40 kg. The weight of 
babies in the EOPE group was 1.623 ± 0.78 kg compared to 2.718 ± 0.51 kg in the LOPE group 
(Figure 3.11). 
 
Baby weights were not normally distributed amongst the study groups.  A Kruskal-Wallis H 
test showed that there was a statistically significant difference in baby weight between the 
different groups, [χ
2
(2) = 76.430; p < 0.000].  The effect of size (η
2
) on the difference in mean 
ranks was 37.7%. 
 
Pairwise Mann Whitney U tests with Bonferroni post hoc analyses (adjusted p < 0.016) showed 
that the normotensive pregnant baby weight differed significantly compared to EOPE (U: 
165.0, p = 0.000) and LOPE groups (U: 1804.5 p = 0.000).  There was a significant difference 
between early onset and late onset groups (U: 268.5; p = 0.000). 
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Furthermore, when the Levene's test was performed comparing the pre-eclamptic group as a 
whole (EOPE + LOPE) to the normotensive group (with/out equal variance), the 2 tailed T-test 
showed a statistical significance of p = 0.000 between babies of the pre-eclamptic mothers 
compared to the normotensive mothers. 
 
 Further,, when considering the effect of HIV on baby weight, the Kruskal-Wallis H test and 
Bonferroni post hoc analysis, demonstrated a statistically significant difference between the all 
cohorts, [(χ
2
(5) = 78.678); p < 0.000; Figure 3.12]. 
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Figure 3.11: Boxplot illustrating baby weight (kg) across all groups based on  HIV status 
 
 
3.2.7 Placental weights across pregnant groups 
In normotensive pregnant patients the mean weight ± standard deviation of the placenta was 
612.45 ± 81.57 g. The mean placental weight in the EOPE group was 430.00 ± 142.23g 
compared to 558.46 ± 35.76 g in the LOPE group (Figure 3.13). 
 
Placental weight was not normally distributed amongst the groups.  A Kruskal-Wallis H test 
showed that there was a statistically significant difference in placental weight between the 
different groups, χ
2
(2) = 15.674, p = 0.000. 
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Statistically significant differences after Bonferroni post hoc analyses (adjusted p < 0.008) 
revealed that there were differences between placenta weight of normotensive pregnant and 
EOPE groups (U: 647.0; p = 0.000). There was no difference between normotensive and the 
LOPE group (p = 0.484).  There was a significant difference between early onset and late onset 
as well (U: 223.0;  p < 0.001).  
 
When considering the effect of HIV on placental weight, the Kruskal-Wallis H test and 
Bonferroni post hoc analysis,  showed a statistically significant difference between the different 
study groups, [(χ
2
(5) = 23.446); p < 0.000], (Figure 3.14). 
 
Figure 3.12: Boxplot showing placental weight (g) across pregnant groups 
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Figure 3.13: Boxplot illustrating effect of HIV status on placental weight (g) 
 
3.2.8 HIV status 
More than half of the sample cohort was HIV negative (n = 179; 54.9%).  Forty five percent 
was HIV positive (n = 147; 45.1%). 
 
3.2.8.1 Cluster of Differentiation 4 (CD4) count (cells/mm
3
) 
HIV positive non-pregnant participants had a mean CD4 count of 473 ± 188.630 cells/mm
3
  (p 
<  0.216) compared to 417.91 ± 198.389 cells/mm
3
 (p < 0.629) in the HIV positive 
normotensive pregnant group. HIV participants with EOPE had a mean CD4 count of 325.38 ± 
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166.036 cells/mm
3
 (SE: 58.703; p < 0.664) compared to 388.08 ± 100.853 cells/mm
3
 (p < 
0.803) in the LOPE group (Figure 3.15).  
 
Figure 3.14: Boxplot showing CD4 count (cells/mm
3
) across study groups 
 
There were no statistically significant differences between group means as determined by one-
way ANOVA [F (3,138) = 0.930; p < 0.428]. 
 
After considering the effect of HIV, the Kruskal-Wallis H test and Bonferroni post hoc 
analysis, demonstrated no statistically significant difference between the different 
groups,[(χ
2
(3) = 2.627); p < 0.453], was found (Figure 3.16). 
 - 72 - 
 
 
Figure 3.15: Boxplot illustrating CD4 count (cells/mm
3
) in HIV positive groups 
 
3.2.8.2 Anti – retroviral (ARV) Usage  
Antiretroviral therapy was received by 36.6% of the non-pregnant participants compared to the 
63.4% majority within the study population that received ARVs. Some of the pregnant 
participants (18.6%) did not take ARVs compared to 81.4% of pregnant participants that did 
take ARVs therapy.  With regards to ARV usage, a Pearson Chi– square test demonstrated a 
statistically significant difference p < 0.009, between the pregnant and non-pregnant groups. 
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Table 3.1 Demographic data of study groups 
 
 
Non Pregnant Normotensive 
pregnant 
EOPE LOPE   
N = 120 N = 118 N = 32 N = 52 
Age (y) 33.01 ± 7.8 25.61 ± 5.7 27.78 ± 6.1 28.55 ± 7.5 
Maternal Weight (kg) 75 ± 13 73 ± 13.8 81.75 ± 15 82 ± 19.7 
Systolic (mmHg) 133 ± 26 117 ± 9.3 168 ± 8 161 ± 22 
Diastolic (mmHg) 77 ± 15 73 ± 85 109 ± 16.9 96.5 ± 7.6 
Height (m) 1.563 ± 0.113 1.574 ± 0.0676 1.563 ± 0.0158 1.593 ± 0.0751 




473 ± 188 417 ± 198 325 ± 166 388 ± 100 
Gestational Age (wks) 0 38.98 ± 1.5 32 ± 3.8 36.92 ± 1.847 
Baby weight (kg) - 3.23 ± 0.058 1.623 ± 0.274 2.716 ± 0.1422 
Placental weight (g) - 612.45 ± 11.89 430 ± 50.28 558.46 ± 37.65 
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3.3 ANTHROPOMETRIC DATA ACROSS STUDY GROUPS 
 
3.3.1 Maternal Weight 
The mean weight ± standard deviation of the non-pregnant women was 75.0 ± 13.14 kg 
compared to 73.17 ± 13.89 kg of the normotensive pregnant women. The mean weight of 
EOPE women was 81.75 ± 15.06 kg compared to 82.523 ± 19.71 kg of LOPE women (Table 
3.1). 
  
When considering the effect of HIV on maternal weight, the Kruskal-Wallis H test and 
Bonferroni post hoc analysis, showed no statistically significant difference between the 
different groups,[(χ
2
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Figure 3.16: Boxplot illustrating maternal weight (kg) across HIV groups 
 
3.3.2 Maternal Height  
The mean height of non-pregnant women was 1.563 ± 0.113 m whilst that of normotensive 
participants was 1.574 ± 0.676 m. The mean height was 1.531± 0.090 m and 1.593 ± 0.075 m 
in EOPE and LOPE women, respectively (Table 3.2).  
 
After considering the effect of HIV across the categories, the Kruskal-Wallis H test and 
Bonferroni post hoc analysis, demonstrated no statistically significant difference between the 
different groups,[(χ
2
(7) = 6.119); p < 0.526]. 
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3.3.3 Maternal Body mass index 
The BMI of the non-pregnant and normotensive pregnant women was 28.55 ± 4.24 kg/m
2
 and 
28.89 ± 6.80 kg/m
2
, respectively. The mean BMI of EOPE and LOPE women was 32.73 ± 7.65 
kg/m
2
 and 32.97 ± 8.54 kg/m
2
 respectively (Figure 3.18). The mean BMI of the study 
population fell into either the overweight (BMI - 27.5 – 30 kg/m
2
) or mildly obese categories 




Body mass index per group was not normally distributed.  After log10 transformation of the 
data, a one way ANOVA revealed no statistically significant difference between the groups [F 
(3,322) =1.161; p = 0.325].Whilst there was a significant difference between the non-pregnant 
and pregnant cohorts, there was no statistically significant differences between the 
normotensive, EOPE and LOPE groups (p = 0.325). Likewise, the distribution of BMI was the 
same across the categories with respect to HIV status (p = 0.124). 
 
After considering the effect of HIV across the categories the study found that after the Kruskal-
Wallis H test and Bonferroni post hoc analysis, no statistically significant difference between 
the different groups,[(χ2(7) = 9.330); p < 0.230], was found (Figure 3.19). 
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Figure 3.17: Boxplot showing BMI (kg/m
2
) across study groups 
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Figure 3.18: Boxplot showing BMI (kg/m
2
) across subgroups based on HIV status 
 
3.3.4 Mid upper arm circumference (MUAC) 
The mid upper arm circumference was 31.53 ± 2.63 cm in non-pregnant women compared to 
28.38 ± 4.59 cm in the normotensive pregnant women. EOPE participants had a MUAC of 
33.38 ± 4.69 cm compared to28.23 ± 1.43 cm in the LOPE group (Figure 3.20; Table 3.2). 
 
One way ANOVA tests of both mid-upper arm circumference [F(3.322) = 5.740; p = 0.01] and 
triceps skinfold thickness [F(3.322) = 5.411; p = 0.001] showed that there was significant 
difference between at least one of the groups analysed.   
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Post hoc tests showed that the mean MUAC for non-pregnant  women (31.53 ± 5.845 cm) was 
significantly higher than normotensive pregnant women (28.73 ± 4.717 cm; p < 0.000) but not 
significantly different from EOPE and LOPE groups.  
 
 
Figure 3.19: Boxplot showing mid arm circumference (cm) across study groups 
 
When considering the effect of HIV, it was shown that after the Kruskal-Wallis H test and 
Bonferroni post hoc analysis, a statistically significant difference between the different 
groups,[(χ
2
(7) = 23.253); p < 0.002], was found (Figure 3.21). 
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Figure 3.20: Boxplot illustrating mid arm circumference (cm) based on HIV status 
 
3.3.5 Triceps skin fold thickness 
Fisher’s Least significant difference post hoc test revealed that  triceps skin fold thickness in 
the normotensive pregnant group (18.14 ± 7.025 mm) was significantly  lower than both non-
pregnant (21.58 ± 8.812 mm; p < 0.002) and LOPE (22.89 ± 10.638 mm)  groups but not 
significantly different from the EOPE group (18.94 ± 9.148 mm) (Table 3.2; Figure 3.22). The 
triceps skin fold thickness in the EOPE group was lower than LOPE group (p < 0.036). 
 
Non-pregnant women had a mean triceps skin fold thickness of 13 ± 4.69 mm compared to 
18.34 ± 7.08 mm in normotensive women. The mean triceps skin fold thickness in EOPE and 
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LOPE women was 23.38 ± 12.18 mm and 16.90 ± 8.47 mm respectively. There was a 
statistically significant difference in triceps skin fold thickness between the normotensive group 
and other groups (p < 0.000). There were no other statistically significance between non 
pregnant, EOPE and LOPE groups. 
 
 
Figure 3.21: Boxplot of mean triceps circumference (mm) across study groups 
 
After analysing  the effect of HIV on triceps skinfold thickness across the groups, it was found 
that after the Kruskal-Wallis H test and Bonferroni post hoc analysis, a statistically significant 
difference between the different groups, [(χ
2
(7) = 20.457); p < 0.005], was shown across the 
categories (Figure 3.23). 
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Table 3.2: Anthropometric and CD4 data across study groups 
 
 
Non Pregnant Normotensive 
Pregnant 
EOPE LOPE   
N = 120 N = 118 N = 32 N = 52 
Height (m) 1.563 ± 0.113 1.574 ± 0.0676 1.563 ± 0.0158 1.593 ± 0.0751 
BMI (kg/m
2
) 28 ± 4.2 28.8 ± 6.8 32.7 ± 7.6 32.97 ± 8.5 
MUAC (cm) 26 ± 2.6 28±4.5 33 ± 4.6 28.23 ± 5.1 
Triceps skin fold (cm 21.58 ± 4.6 18.14 ± 7.07  18.94 ± 12 22.89 ± 8 
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3.4 ASSESSMENT OF SERUM LEVELS OF ADIPONECTIN USING ELISA  
The median adiponectin level was 446.55700 µg/ml and ranged between 305.27050 - 
725.32175 µg/ml. The mean adiponectin level was 897.93 (p < 0.080); 17.19 (p < 0.000); 23.16 
(p < 0.017); 24.61 (p < 0.324), in the non-pregnant, normotensive pregnant, EOPE and LOPE 
participants, respectively (Table 3.3).   
 
The effect of HIV on adiponectin across the categories, using the Kruskal-Wallis H test and 
Bonferroni post hoc analysis, showed a statistically significant difference between the different 
groups, [(χ
2
(7) = 24.540); p < 0.001] (Figure 3.24). 
 
Figure 3.23: Boxplot illustrating adiponectin (µg/ml) based on HIV status 
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3.5 ASSESSMENT OF SERUM LEVELS OF LEPTIN USING THE LUMINEX 
TECHNIQUE 
The median leptin concentration was 153.00 pg/ml) with an inter quartile range of 64.25 – 
3028.06 pg/ml. Non-pregnant participants had mean leptin concentrations of 4887.25 pg/ml (p 
< 0.125) compared to 2732.27 (p< 0.000) in the normotensive pregnant groups. Participants 
with EOPE had a mean leptin concentration of 955.75 (p < 0.000) compared to 310.23 (p < 
0.000) in the LOPE groups.  When considering the effect of HIV on mean leptin level using the 
Kruskal-Wallis H test and Bonferroni post hoc analysis, a statistically significant difference 
between the different groups,[(χ
2
(7) = 16.926); p < 0.018], across the categories was noted 
(Figure 3.25). 
 
Figure 3.24: Boxplot illustrating leptin (pg/ml) based on HIV status 
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3.6 ASSESSMENT OF SERUM LEVELS OF TNFα USING LUMINEX TECHNIQUE 
Non-pregnant participants did not have measurable levels of TNF-α. Normotensive participants 
had a mean TNF-α concentration of 608.521 pg/ml (p = 0.000). Participants with EOPE had a 
mean TNF-α concentration of 661.03 (p = 0.000) compared to 616.439 (p = 0.000) in the LOPE 
group (Table 3.3).  
 
After considering the effect of HIV on TNF-α concentration, the Kruskal Wallis test and post 
hoc Bonferroni analyses revealed a statistically significant difference, [(χ
2
(7) = 14.160); p < 





 - 87 - 
 
Figure 3.25: Boxplot illustrating mean TNF-α (pg/ml) based on HIV status 
 
 
3.7 ASSESSMENT OF SERUM LEVELS OF RESISTIN USING THE LUMINEX 
TECHNIQUE 
Non-pregnant participants had a mean resistin concentration of 7497.13 pg/ml compared to 
3536.50 pg/ml in the normotensive pregnant groups. The mean resistin concentration was 
1017.63 pg/ml in the EOPE group compared to 286.92 pg/ml (p < 0.000) in the LOPE group.  
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When considering the effect of HIV on resistin concentration, the Kruskal-Wallis H test and 
Bonferroni post hoc analysis, a statistically significant difference between the different groups, 
[(χ
2
(7) = 18.625); p < 0.009], was noted (Figure 3.27). 
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Table 3.3: Detailed outline of adipokine levels across study groups 
 Non Pregnant Normotensive 
Pregnant 
EOPE LOPE  
N = 120 N = 118 N = 32 N = 52 
ADIPONECTIN  
µg/l 
897.93 ± 126.18 17.19 ± 11.568 23.16 ± 21.392 24.61 ± 12.869 
LEPTIN  
pg/ml 
4887.25 ± 705.294 2732.27 ± 580.183 955.75 ± 527.642 310.23 ± 177.438 
TNF-α  
pg/ml 
0 608.52 ± 84.899 661.036 ± 202.604 616.439 ± 117.53 
RESISTIN  
pg/ml 
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Table 3.4: Adipokine levels in relation to BMI groups 
 5 10 25 50 75 90 95 
BMI 22.75 23.94 26.19 30.14 34.95 40.42 44.22 
ADIPONECTIN  
µg/ml 
142.06 192.78 305.27 446.56 725.32 1061.39 1371.04 
LEPTIN  
pg/ml 
50.00 51.00 64.25 153.00 3028.06 7827.25 11235.38 
RESISTIN  
pg/ml 
50.00 56.50 71.00 168.00 3085.13 9849.75 12921.25 
TNF  
pg/ml 
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3.8 ANALYSIS OF RESULTS WITH RESPECT TO THE PRIMARY NULL 
HYPOTHESES OF THE STUDY 
3.8.1 Null hypothesis: The levels of adiponectin/leptin/resistin/TNF-α does not differ 
amongst the pregnant and non-pregnant cohorts. 
 
The levels of TNFα/adiponectin/leptin and resistin were all statistically significantly different 
between the pregnant and non-pregnant cohorts (Table 3.5). The mean concentration of TNF-α 
was 22.181 ± 90.24 pg/ml (p = 0.000) in the pregnant cohort. In this pregnant cohort, the mean 
concentration of adiponectin, leptin and resistin was 614.980 µg/l ± 780.84 (p = 0.000); 
2266.537 pg/l ± 3747.85 (p = 0.000) and 2790.471 pg/l ± 5363.09 (p = 0.000), respectively. 
 
The levels of TNF-α, leptin and resistin were significantly different within the normotensive 
pregnant versus pre-eclamptic groups. Using the Mann-Whitney test it was demonstrated that 
TNF- α was statistically significant within the pregnancy groups (p < 0.044). Likewise, leptin 
(p < 0.004) and resistin (p < 0.006) were statistically significant between the pregnancy groups.  
Only Adiponectin, as mentioned, failed to reach statistical significance within the pregnancy 
subgroups (p < 0.292). 
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Table 3.5: Detailed outline of adipokine levels between pregnant vs non-pregnant study groups 
 PREGNANT     NON PREGNANT 
 Median Minimum Maximum  Median Minimum Maximum p-values 
TNF-α  
pg/ml 
0 0 524  0 0 942 0.00 
Adiponectin 
µg/l 
476.7 27 11099  414.6 66 5030 0.00 
Leptin  
pg/ml 
189.0 50 19239  88.0 50 14507 0.00 
Resistin 
pg/ml 
230.0 50 58241  101.0 50 17338 0.00 
 
 
3.8.2 Null hypothesis: The levels of adiponectin/leptin/resistin/TNF-α does not differ in 
women who develop early onset pre-eclampsia as compared to women who develop late 
onset pre-eclampsia 
 
The differences in TNF-α, adiponectin, leptin and resistin concentration failed to reach 
statistically significant p-values between EOPE versus LOPE using the Mann-Whitney Test. 
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Table 3.6: Detailed comparison of adipokine levels between EOPE and LOPE study groups 
 LOPE EOPE 
 Median Minimum Maximum Median Minimum Maximum p-values 
TNF-α 0 0 297 0 0 392 <0.098 
Adiponectin 554.3 27 1957 446.2 168 1931 <0.913 
Leptin 196 50 58241 182 50 13467 <0.538 
Resistin 230 50 58241 230.5 50 16763 <0.669 
 
 
3.8.3 Null hypothesis: The levels of adiponectin/leptin /resistin /TNF-α in pre-eclamptics 
does not differ according to HIV status 
 
There were no statistically significant differences in the levels of TNF-α, adiponectin, leptin 
and resistin in the pre-eclamptic HIV+ve versus the HIV-ve groupings.  In this instance the null 
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Table 3.7: Detailed comparison of adipokine levels between HIV negative and positive study 
groups 
 HIV-ve HIV+ve 
 Median Minimum Maximum Median Minimum Maximum p-values 
TNF-α  
pg/ml 
0 0 392 0 0 346 <0.696 
Adiponectin 
µg/l 
453.6 167 1889 559.5 60 1957 <0.499 
Leptin  
pg/ml 
185 50 13495 196 55 19239 <0.800 
Resistin 
pg/ml 
230.5 50 58241 191 50 16763 <0.671 
 
 
3.8.4 Null hypothesis: The difference in levels of adiponectin/leptin/resistin/TNFα in 
women who develop early onset pre-eclampsia as compared to women who develop late 
onset pre-eclampsia are not altered by the HIV status of the patients. 
 
The study results from use of the Mann-Whitney Test demonstrated that there were no 
statistically significant differences in the levels of adiponectin, leptin, TNF-α and resistin 
within the pregnancy groups with respect to HIV status.  The levels for TNF-α was p < 0.665; 
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3.9 FURTHER, COMPARISONS 
3.9.1 CD4 Count 
 
There was no statistically significant findings in the levels of TNF-α, adiponectin, leptin and 
resistin within the HIV+ve pregnant population based on CD4 >350 compared to CD4 <350 
(Table 3.8). 
 
Table 3.8: Detailed comparison of adipokine levels based on CD4 levels.  
 CD4 < 350 CD4 ≥ 350 
 Median Minimum Maximum Median Minimum Maximum p-values 
TNF pg/ml 0 0 346.446 0 0 523.552 0.386 
Adiponectin 
ug/l 
601.51 117 3954 505.1 59.7 1252 0.122 
Leptin pg/ml 277 53 13467 279 50 19239 0.848 




There were no statistically significant differences in the levels of adiponectin /leptin /resistin 
/TNF-α in pregnant HIV+ve women based on receipt of HIV therapy. TNF-α achieved a p 
value of 1 whilst adiponectin (p < 0.735), leptin (p < 0.215) and resistin (p < 0.326) across 
groups. 
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3.9.3 BMI 
There were no statistically significant differences in levels of TNF-α, Leptin, and Resistin when 
compared across subdivisions of BMI in the non-pregnant population (Table 3.4). TNF-α 
achieved a p < 0.933 vs leptin that achieved a p < 0.234 vs resistin that achieved a p < 0.108. 
However adiponectin levels did reach statistical significance amongst the BMI subdivisions in 
the non-pregnant population; p < 0.002. 
 
There were no statistically significant differences in the levels of TNF-α, adiponectin, leptin 
and resistin in the pregnant population across the subdivisions of BMI. TNF-α achieved a p < 
0.466. Adiponectin achieved a p < 0.091 whilst leptin achieved a p < 0.275 and resistin 
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Table 3.9: Adipokine levels stratified according to BMI 
 BMI 
 <27 27 – 30 30-35 >35 
TNF α pg/ml 0.00±105.066 0.00±134.489 0.00±31.083 0.00±60.639 
Adiponectin 
ug/ml 
593.469±617.586 431.988±572.660 396.307±1254.792 403.714±347.278 
Leptin pg/ml 321.00±3479.098 114.00±3057.903 131.00±3836.619 104.00±4427.365 
Resistin pg/ml 320.00±4868.865 130.50±3795.870 128.00±7392.624 109.00±4356.158 
 
Using the data collected it was possible to depict the relationship between TNFα / Adiponectin 
/ leptin and resistin and their medians with respect to change in Body mass index (Table 3.9). 
 
It was possible to further, stratify the median TNFα / Adiponectin / Leptin and Resistin levels 
with respect to pregnancy status and HIV status. This has not been attempted in the local 
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Table 3.10: Adipokine levels according to Pregnancy and Non pregnancy state in relation to HIV status 
 
 Non pregnant Pregnant 
 HIV -ve HIV+ve HIV-ve HIV+ve 
TNFα pg/ml 0.00±189.028 0.00±39.403 0.00±58.609 0.00±72.710 
Adiponectin 
ug/ml 
349.272±300.190 517.943±758.705 452.95±1032.234 557.574±511.288 
Leptin pg/ml 90.00±3029.725 74.50±1791.436 153.00±4128.513 321.00±4037.204 
Resistin pg/ml 101.00±3375.880 90.00±1527.309 175.00±6849.363 283.50±4763.811 
 




4.1 INTRODUCTION - OBESITY, HIV AND PRE-ECLAMPSIA 
Maternal morbidity and mortality in South Africa is weighed down in a quagmire of old and 
new challenges. Currently, pre-eclampsia and HIV infection remain two of the top five causes 
of maternal mortality in South Africa (NCCEMD, 2007). Following on the heels of the HIV 
infection, South Africa now faces a new pandemic, that of obesity.   
 
 In 2011, the overall HIV prevalence amongst antenatal women was 29.5% (95%CI: 28.7- 30.2) 
(Health, 2011a SANDO). Geographical variations of the epidemic in South Africa reflects a 
provincial distribution, with KwaZulu-Natal having the highest HIV prevalence followed by 
Mpumalanga, Free State and North-West, all with prevalence rates greater than 30.0% (Health, 
2011bSANDO). 
 
Concurrently, it has been estimated that 1.3 billion people are overweight or obese (Obesity 
Task Force, 2005). Not only is obesity affecting high income countries but, it is becoming more 
evident and an increasing problem in low-middle income countries (Puoane et al., 2002, 
Filozof et al., 2001, Rivera et al., 2002).  
 
South Africa has the highest overweight and obesity rate in sub-Saharan Africa: seven out of 10 
women have significantly more body fat than what is considered healthy. Of the 70% of 
overweight South African women, 42% are obese (Ng et al., 2014). In neighboring sub-
Saharan African countries such as Namibia (19.8%), Lesotho (24.1%) and Zimbabwe (33.5%) 
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women are less obese than South Africa. Eritrea only has 4.7% obese women and Ethiopia 
1.8% – respectively, a 10-20 fold lower prevalence of obese women than South Africa (Ng et 
al., 2014).  
 
A progressive increase in the prevalence of obesity in South Africa, particularly among women 
and young girls has been reported in many studies (Labadarios et al., 2005, Senekal et al., 
2003, Walker, 1995) A report published by the South African Medical Research Council 
(MRC) in 2007, cited that “56% of adult women and 29% of adult men were overweight/obese, 
while 17% of children under the age of 9 years were overweight” (Walker, 1995, Stein, 2007). 
They also report that “approximately 60 people die from obesity-related disease every day in 
South Africa”. The primary reason for this high mortality amongst Black women, perhaps 
emanates from a strong belief that increased body weight is considered an indicator of wealth, 
good health and success, whilst being thin is associated with being HIV-infected (Mvo et al., 
1999, Ndlovo and Roos, 1999).  
 
Globally, obesity remains a key risk factor for hypertension and cardiovascular disease (WHO, 
2003). Pregnancy, obesity and overweight all lead to increased insulin resistance. Insulin 
resistance is a physiological process in pregnancy, but obesity and overweight leads to 
pathological changes ie., inflammatory processes and sub-clinical inflammation (Challis et al., 
2009, Wang and Nakayama, 2010, Stupin and Arabin, 2014).  
 
TNF-α, leptin, resistin and adiponectin and many other adipokines are released into the 
maternal circulation with increasing obesity. They altogether contribute to the development of 
obesity specific morbidities such as hypertension, diabetes and cardiovascular disorders (Ronti 
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et al., 2006, Fischer-Posovszky et al., 2007). Adipose tissue produces TNF-α, which increases 
with an increasing degree of obesity (Hotamisligil, 1993). This elevation of TNF-α contributes 
to insulin resistance. In 1994,  leptin was identified as a secretory product of adipose tissue 
(Zhang et al., 1994a). Leptin up-regulation contributes to inflammation and changes in 
metabolic activity.  In obesity, adipokines and receptors are up-regulated in visceral adipose 
tissue (VAT) (Ronti et al., 2006, Hu et al., 1996, Milan et al., 2002).  
 
Since two-thirds of HIV infected women of reproductive age reside in sub-Saharan Africa,  this 
region is experiencing a major obstetric dilemma, (Coovadia and Coutsoudis, 2000).  Also, in 
view of the fact that KZN province is considered the epicenter of the global HIV pandemic, 
women of reproductive age are vulnerable. This is further, exacerbated by the high frequency 
of pre-eclampsia, the commonest direct cause of maternal deaths in South Africa.  Hence, it is 
imperative that one adequately clarifies the interaction of the two diseases. 
 
Pregnancy in itself reflects a modest maternal inflammatory response, whilst pre-eclampsia is 
identified as an excessive inflammatory response (Redman and Sargent, 2005, Redman et al., 
1999).  Thus, when combined with the immune insufficiency stimulated by HIV infection, it is 
possible that the immune hyper-reactivity is perhaps prevented, thereby inhibiting pre-
eclampsia development.   
 
A lower incidence of pre-eclampsia in HIV positive women has been reported (Boyajian et al., 
2012); (Wimalasundera et al., 2002, Haeri et al., 2009, Mattar et al., 2004). Similarly, 
consistent evidence has been described in South Africa where HIV positive women were found 
to be at a lower risk of developing pre-eclampsia (Kalumba et al., 2013). In the pre-HAART 
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era, pre-eclampsia was an uncommon complication of pregnancy in HIV-infected women, the 
occurrence being even less frequent than in the general population (Stratton et al., 1999). 
Another study has demonstrated that with the routine use of HAART, the incidence of pre-
eclampsia in HIV-infected pregnant women increases to a level similar to that of HIV-
uninfected women (Wimalasundera et al., 2002). Additionally, the incidence of pre-eclampsia 
and fetal deaths increases in the HIV infected pregnant women (Suy et al., 2006). The latter 
study attributes this risk with the exposure to HAART prior to pregnancy and that insulin 
resistance and endothelial inflammation may have been the potential underlying conditions. 
 
In light of the pervasive HIV infection, high pre-eclampsia prevalence and the very high levels 
of obesity in South Africa, this novel study attempts to reconnoiter the relationship amongst 
this deadly troika. Given the role of this trio in immune responses, this study explores the role 
of adipose related proteins (adipokines) in HIV associated pre-eclampsia in KwaZulu-Natal. 
 
4.2 PATIENT DEMOGRAPHICS 
4.2.1 Maternal age  
In this study, the mean age of pregnant participants was 27.3 vs 26.3 vs 26.6 years in the 
normotensive pregnant, EOPE and LOPE cohorts, respectively. These maternal ages appear to 
be largely in keeping with global trends of women delaying their first pregnancy. However, one 
should take into consideration that due to ethical considerations, maternal age of under 18 years 
was an exclusion criteria in the sampling strategy of this study.  
 
The younger participants in the EOPE cohort is supported by classical risk factors such as 
nulliparity (Luo et al., 2007), Black ethnicity  and primipaternity (Zhang et al., 1997, ACOG, 
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2002), all of which are risk factors for pre-eclampsia  development. The age of the 
normotensive pregnant cohort in this study is similar to that of previous studies 
(Aksornphusitaphong and Phupong, 2013). 
 
The distribution of HIV according to age demonstrates that the HIV positive participants 
tended to be older than the HIV negative participants. This attests to the fact that local 
incidence of the HIV disease seems to be stabilizing, as supported by local statistics (Lehola, 
2014). 
 
4.2.2 Blood pressure 
Currently both the International Society for the Study of Hypertension in Pregnancy and the 
Working Group of the National High Blood Pressure Education Program in the United States 
both define pre-eclampsia as either systolic blood pressure ≥140 mm Hg or diastolic blood 
pressure ≥90 mm Hg, with associated proteinuria after 20 weeks’ gestation (Brown et al., 2001, 
2000 and 183(1):S1-S22). As expected there were statistically significant higher systolic and 
diastolic blood pressure readings in this studys’ pre-eclamptic cohort as compared to the 
normotensive non-pregnant and normotensive pregnant population. Furhermore, it was found 
that there were statistically significant differences with respect to HIV status and blood 
pressure across the non-pregnant, pre-eclamptic and normotensive cohorts (p=0.000). 
 
A posturing inspection of BP in this study revealed a trend towards a lower systolic and 
diastolic blood pressure in HIV naive individuals. This trend is in keeping with the 
development of insulin resistance, obesity and hypertension in HIV infection (Gazzaruso et al., 
2003). Furthermore,, it is well documented that the use of HAART induced complications of 
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metabolic syndromes such as impaired glucose tolerance, diabetes, hypertriglyceridemia, and 
reduced levels of high-density lipoprotein (HDL) are risk factors for cardiovascular disease 
development, including blood pressure elevation (Hadigan et al., 2001) (Samaras et al., 2007, 
Wolz et al., 2000); (Carr et al., 1998a, Samaras et al., 2007, Carr et al., 1998c, Carr et al., 
1998b). 
 
4.2.3 Gestational age, birth weights and placental weights 
This study demonstrates significant differences in the gestational age at delivery when 
comparing the normotensive pregnant, EOPE, and LOPE cohorts ie., 38.98 vs 32 vs 36.92 
weeks gestation. Similarly, and as expected there were significant differences in the birth 
weight of the pregnant cohort (p=0.000). Babies in the EOPE cohort were significantly smaller 
than both, the normotensive pregnant or LOPE groups (p=0.000) whilst there was no difference 
in birth weight between the normotensive pregnant and LOPE cohorts. This finding is in 
keeping with other studies, where babies from the EOPE cohort fell into the very low birth 
weight category (Kucukgoz Gulec et al., 2013, Lisonkova and Joseph, 2013). Both type of 
pregnancy (EOPE) and HIV status were risk factors for low birth weight in this study. 
 
A large scale Tanzanian study in 2001 found that socio economic status, vitamin deficiency, 
parasitic infection, HIV positivity and stage of disease as risk factors for lower birth weight. 
When examining the effect of HIV status on baby weight in this study, lower birth weight 
babies in the EOPE HIV positive participants compared to the LOPE HIV 
negative/normotensive pregnant HIV positive and negative cohorts are found, respectively. In 
this study birth weight was lower in the EOPE HIV negative participants when compared to the 
LOPE HIV negative and normotensive pregnant HIV negative/positive participants 
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respectively. The LOPE HIV negative group also had lower birth weight babies than the 
normotensive HIV negative group. LOPE HIV positive participants had lower birth weight 
when compared to the normotensive pregnant HIV positive/negative participants. 
 
Although earlier studies by Minkoff et al., (1990) found no association between HIV infection 
and risk for low birth weight, these were small studies.  Notably they did not consider the stage 
of HIV disease (Minkoff et al., 1990).  Likewise, later studies also did not show a correlation 
(Castetbon et al., 1999). In contrast, studies by Stratton et al., (1999) support the correlation of 
low birth weight with HIV infection (Stratton et al., 1999).  
 
Infant birth weight does not differ among women in the earlier stages of HIV disease, but has 
been shown to decrease significantly in stage III than in stage I infection (Dreyfuss et al., 
2001). This may be attributed to the fact that with increased HIV infection, the immune system 
is further, down regulated eventuating in a deterioration of nutritional reserves. 
 
Similarly, this study reports statistically significant smaller placentas in the EOPE cohort 
compared to the other pregnancy cohorts.  There was however, no difference between the 
normotensive and LOPE pregnant cohorts. This outcome is indicative of the difference in 
pathophysiology between the EOPE and LOPE cohorts. Early onset pre-eclampsia is 
characterized by abnormal placentation and resultant hypoxia.  It is also is consistent with the 
<34 weeks gestational age in the EOPE group. Moreover, poor fetal/neonatal outcomes 
particularly, lower birth weight  has been previously reported in the EOPE group (Lisonkova 
and Joseph, 2013). The shallow placentation with resultant decreased blood flow and ensuing 
lower placental weight in the EOPE group expounds placental inefficiency.  
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Indications for delivery and complications 
In this study, the indications for delivery were in fetal interest, with the commonest 
complication being one case of abruption placentae (3%), nine cases of eclampsia (27%), five 
cases of imminent eclampsia (15%) and twelve cases of severe pre-eclampsia (36%). 
Moreover, there were six cases (18%) of stillbirths. 
 
 In the study by Minire et al., (2013), maternal complications in pre-eclampsia were examined 
precisely and showed that liver damage occurred in 4.9% and 12.3% had renal impairment. 
Detachment of the placenta (abruption) was encountered in 7% of cases and 0.7% of patients 
had an epileptic attack in the study by Minire et al., (Minire et al., 2013). HELLP syndrome 
was present only in 4.2%, pulmonary edema occurred in 5.6% of subjects, DIC was found in 
2.8% of cases and only one patient (0.2%) was registered with encephalopathy (Minire et al., 
2013). 
 
As the researcher was unable to obtain liver and renal function test results in all participants it 
is not possible at this time to speculate on the true incidence of liver and renal dysfunction in 
the local setting. This would have been an interesting area of investigation, as there may be 
contributory disease to these organs with use of various antiretroviral drugs. 
 
4.2.4 HIV status / CD4 / ARV usage 
The estimated overall HIV prevalence rate is approximately 10,2% of the total South African 
population (Lehola, 2014). The total number of people living with HIV is estimated to be 
approximately 5.51 million in 2014. For adults, aged 15–49 years, an estimated 16.8% of the 
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population is HIV positive (Lehola, 2014). As per study design and inclusion criteria, forty five 
percent (45.1%) of the overall study population was HIV infected. It must be noted that the 
study was conducted at a large referral hospital, there is a higher number of HIV positive 
individuals in such a setting. Further, in the Obstetric ward, a younger population tends to be 
the norm and this is a high risk group for the development of sexually transmitted infections. 
This study specifically included participants in the 18-45yr age group, an age group that carries 
the highest incidence of HIV nationwide (Lehola, 2014).  As participants were of a similar age 
throughout the study groups their time of exposure to HIV infection may be similar.  
 
As the national government had instituted policy at the time of the study, that all pregnant 
women with a CD4 count less than 350 cells/mm
3
 be commenced on an ARV triple regimen 
and those with a CD4 >350 receive PMTC this may explain the significant difference in ARV 
usage between the non-pregnant and pregnant populations. 
 
4.3 ANTHROPOMETRIC MEASUREMENTS 
4.3.1 BMI 
In this study, significant differences in the BMI between the non-pregnant and pregnant groups, 
but no significant differences between the pregnant cohorts were noted. BMI was calculated on 
individuals in their third trimester of pregnancy. To date there is no standardised way to 
calculate BMI in pregnancy.  BMI is based on population and ethnicity specific charts, however 
these charts are unavailable as yet for the SA region (to our knowledge).  There have however 
been comparisons made within the North American adolescent population (Lynch et al., 2007) 
and as well as a WHO expert consultation on obesity in Asian populations (WHO Expert 
consultation, 2004) .  
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The WHO Expert Consultation concluded that the proportion of Asian people with a high risk 
of type 2 diabetes and cardiovascular disease was still substantial at BMI's lower than the 
existing WHO cut-off point for overweight (= 25 kg/m
2
) (WHO Expert consultation 2004) . 
However, the cut-off point for observed risk had varied from 22 kg/m
2
 to 25 kg/m
2
 amongst the 
different Asian populations and for the high risk cohorts, it varied from 26 kg/m
2
 to 31 kg/m
2
 
(WHO Expert consultation, 2004). The Consultation, therefore, recommended that the current 
WHO BMI cut-off points should be retained as the international classification.  
 
The cut-off points for BMI of 23, 27.5, 32.5 and 37.5 kg/m
2
 were recommended for use as 
points for public health action. This same consultation recommended that countries should use 
all categories (i.e. 18.5, 23, 25, 27.5, 30, 32.5 kg/m
2
 , and in many populations, 35, 37.5, and 40 
kg/m
2
) for reporting purposes, with a view to facilitating international comparisons (WHO 
Expert consultation, 2004). Study analysis showed that the BMI of the non-pregnant and 
normotensive pregnant women was 28.55 ± 4.24 kg/m
2
 and 28.89 ± 6.80 kg/m
2
, respectively, 
although there was no statistically significant difference. 
 
The relationship between BMI and hypertension in subpopulations of  Ethiopian, Vietnamese 
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Table 4.1: The International Classification of adult as underweight, overweight and obesity 





Principal cut-off points Additional cut-off points 
Underweight <18.50 <18.50 
     Severe thinness <16.00 <16.00 
     Moderate thinness 16.00 - 16.99 16.00 - 16.99 
     Mild thinness 17.00 - 18.49 17.00 - 18.49 
Normal range 18.50 - 24.99 
18.50 - 22.99 
23.00 - 24.99 
Overweight ≥25.00 ≥25.00 
     Pre-obese 25.00 - 29.99 
25.00 - 27.49 
27.50 - 29.99 
     Obese ≥30.00 ≥30.00 
          Obese class I 30.00 - 34.99 
30.00 - 32.49 
32.50 - 34.99 
          Obese class II 35.00 - 39.99 
35.00 - 37.49 
37.50 - 39.99 
          Obese class III ≥40.00 ≥40.00 
Source: Adapted from WHO, 1995, WHO, 2000 and WHO 2004. 
 
 
The comparison between the pregnant cohorts allows for a more uniform comparison, however 
the majority of the participants fell into the overweight, pre-obese and grade 1 obesity category. 
Duckitt and Harrington found that raised BMI is a risk factor for pre-eclampsia development. It 
is only plausible to link the finding of similar BMI amongst the normotensive and pre-
eclamptic cohorts in this study to a high pre-pregnancy weight.  Pre-pregnancy weight was not 
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available for the participants. A consideration of high pre-pregnancy weight is conceivable 
since 70 % of South African women are considered overweight. 
 
4.3.2 Mid upper arm circumference (MUAC) 
In this study, the non-pregnant cohort (31.53 ± 2.63 cm) had a significantly higher mid upper 
arm circumference in comparison to the normotensive pregnant cohort (28.38 ± 4.59 cm). 
However, there was no difference between the pre-eclamptic cohorts. The EOPE group had a 
mid upper arm circumference of 33.38 ± 4.69 cm compared to 28.23 ± 1.43 cm for the LOPE 
group. According to the SPHERE (Statewide Partnership for HIV Education in Recovery 
Environments, 2011) Guidelines, mid upper arm circumference may be used as a screening tool 
for pregnancy weight, e.g., as a criterion for entry into a feeding programme. The guidelines 
recommends a cut-off point for risk with a range from 21 - 23 cm.  
 
Furthermore,, mid upper arm circumference is considered a good indicator of the protein 
reserve of a body, and a thinner arm reflects wasted lean mass, ie., malnutrition (Cogill, 2003). 
The WHO Collaborative Study of 1995 implicates mid upper arm circumference values of <21-
23 cm (OR 1.9; 95%; CI: 1.7-2.1) as having significant risk for low birth weight babies (WHO 
1997, Kelly et al., 1996, WHO 1995). 
 
The findings are in keeping with a South African survey of 2002 which depicts an increasing 
mid upper arm circumference amongst Black South African women (Puoane et al., 2002). 
Obesity is a risk factor for hypertension and cardiovascular development. It is also in keeping 
with the recent report showing high levels of overweight and obesity in adult women (Ng et al., 
2014). 
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When comparing the effect of HIV status on the mid upper arm circumference, it was 
demonstrated that normotensive HIV positive participants had a lower MUAC when compared 
to the non-pregnant HIV negative or the LOPE HIV negative participants. This finding is 
congruent with the Womens’ Inter-Agency study that found the incidence of peripheral and 
central lipo-atrophy amongst HIV-infected women to be double that amongst HIV-uninfected 
women, after adjustment for age and race (Tien et al., 2003). A drawback of the latter study 
was that it did not include pregnant women. Obviously due to pregnancy it was not possible to 
assess central lipo-atrophy in this study. 
 
Supportive evidence for this local study findings has been put forward by Villamor et al., 
(2002). They examined lipodystrophy amongst pregnant participants of a low socio-economic 
class, HIV-positive mothers had an adjusted 34% excess prevalence of wasting, compared with 
HIV- negative women (Villamor et al., 2002). 
 
4.3.3 Triceps skin fold thickness (TST) 
This study demonstrated that the triceps skin fold thickness was significantly lower in the 
normotensive pregnant women (18.14 ± 7.025 mm) compared to both non-pregnant (21.58 ± 
8.812 mm; p < 0.002) and LOPE (22.89 ± 10.638 mm) but was not significantly different from 
the EOPE group (18.94 ± 9.148 mm).  
 
It had long been established that “at nearly all sites, skinfold thicknesses increases up to about 
30 weeks of pregnancy” (Taggart et al., 1967). Increases were shown to be greater at central 
and least at peripheral sites, and were not proportional to the initial skinfold thickness. From 30 
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to 38 weeks of pregnancy, the distribution pattern of skin fold thickness had been found to be 
variable: the mid-thigh skinfold increased whilst at other sites there was little change or a 
decrease was noted. All sites decreased between 38 weeks of pregnancy and the end of the first 
post-partum week. Evidence at that time suggested that this change, was not related to the 
presence or absence of oedema, and occurred about the time of parturition (Taggart et al., 
1967). 
 
A later study by Sidebottom et al. revealed that the subcutaneous body fat stores of healthy 
pregnant women remained stable (p>0.13) during the first 6 weeks after conception, and 
increased from 6 to 35 weeks by 1.5 mm at the triceps, 4.2 mm at the subscapular, and 7.3 mm 
(p<0.01) at the thigh areas (Sidebottom et al., 2001). 
 
In this study, the normotensive pregnant participants delivered at ±38.9 weeks whilst the EOPE 
participants delivered at ± 32 weeks of gestation. Superficially it would seem reasonable to 
assume that since EOPE participants delivered at an earlier gestation this would account for the 
seemingly higher TST levels in this cohort. True significance would only be established if the 
participants TST had been established pre-pregnancy, through the different trimesters of 
pregnancy and into the postpartum period. 
 
When considering the effect of HIV status on the triceps skinfold thickness, the normotensive 
HIV positive participants had a significantly lower TST when compared to the LOPE HIV 
negative cohort. The study results are congruent with peripheral muscle wasting observed in 
HIV positive patients (Dannhauser et al., 1999). This is an area requiring supplementary 
research. 
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4.4 ADIPOKINE LEVELS 
4.4.1 Adiponectin 
In this study,  a mean adiponectin level during the third trimester (all bloods were obtained just 
prior to delivery) of pregnancy was found to be 897.93 µg/ml vs 17.19 µg/ml vs 23.16 µg/ml vs 
24.61 µg/ml in the non-pregnant, normotensive pregnant, EOPE and LOPE cohorts, was found 
respectively. 
 
Ukkola et al., (2002) demonstrated an inverse relationship between adiponectin levels and the 
degree of adiposity present. It would seem logical to assume that adiponectin levels would be 
lower in a pregnant state due to increased levels of adipose tissue – as is the trend in this local 
study. However, Nien et al., (2007b) found that there was no significant difference in 
adiponectin levels in the non-pregnant and pregnant state. 
 
An Egyptian study in 2011 found that “serum adiponectin levels in pre-eclamptic women were 
significantly higher than in normal pregnant women and the increase was more marked in cases 
of severe pre-eclampsia”(Abd-Alaleem et al., 2011). Nien et al., (2007a) in a study on severe 
pre-eclampsia had similar findings. This study showed a trend of higher adiponectin levels in 
the preeclamptic cohort as a whole as compared to the normotensive cohort but this failed to 
reach statistical significance (p= 0.292).  
 
It could of course be that this is actually a true reflection that there is no significant increase in 
adiponectin levels in preeclapsia (O'Sullivan et al., 2006, Odden et al., 2006, Dalamaga et al., 
2011). This is possible as the study reflects a high risk population of the same ethinicity at a 
single time frame in pregnancy. Although insulin resistance is thought to play a pivotal role in 
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The reference range of leptin is 3600 – 72400 pg/mL in adult females (Biorad diabetic assay). 
In this study it was found that non-pregnant participants had a mean leptin concentrations of 
4887.25 compared to 2732.27 pg/ml in the normotensive pregnant groups. Participants with 
EOPE had a mean leptin concentration of 955.75 compared to 310.23 pg/ml in the LOPE 
groups (p=0.000). These were statistically significant findings. 
 
The findings in the current study of higher leptin levels in the EOPE cohort as compared to the 
LOPE cohort seems in keeping with many other studies, however the overall finding of lower 
levels of leptin in the pre-eclamptics as a group compared to the normotensive cohort requires 
further, investigation ((Anato et al., 2000, Martinez-Abundis et al., 2000, El Shahat et al., 
2013). It may be possible that the rise in leptin was ameliorated by the use of anti-
hypertensives. The relative difference in leptin levels within the pre-eclamptic cohort may point 
to leptin being a marker for the degree of severity of the pre-eclampsia. Thus far debate 
remains ongoing regarding the role of leptin in pre-eclampsia. 
 
4.4.3 TNF-α 
TNF-α has a reference range of 42 – 203 pg/ml (Biorad Diabetes Assay kit). The current study 
showed non-pregnant participants had no measurable TNF-α levels. This may be attributed to 
the rapid breakdown of TNF-α once drawn from the participants. Normotensive participants 
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had a mean TNF-α concentration of 608.521 pg/ml. Participants with EOPE had a mean TNF-α 
concentration of 661.03 compared to 616.439 pg/ml in the LOPE group (p=0.000).  
 
Walsh et al., (2013) have shown that insulin resistance, even at levels below those diagnostic of 
gestational diabetes, is associated with maternal and fetal inflammatory response. Hence an 
elevated TNFα level is expected as compared to a healthy non pregnant population. Further, 
Vitoratos et al., (2010) found that the levels of TNF-α were significantly elevated in 
preeclamptic as compared to normotensive pregnant participants. Similar findings in were 
shown in this study and this was found to be statistically significant (p=0.000). 
 
4.4.4 Resistin 
The reference range of resistin is 6390 – 26400 pg/ml (Biorad Diabetic assay). This local study 
found that non-pregnant participants had a mean resistin concentration of 7497.13 pg/ml 
compared to 3536.50 in the normotensive pregnant groups. The mean resistin concentration 
was 1017.63 pg/ml in the EOPE group compared to 286.92 pg/ml in the LOPE group 
respectively.   
 
4.5 ADIPONECTIN, LEPTIN, RESISTIN AND TNF-α DIFFERENCES IN NON 
PREGNANT VERSUS PREGNANT POPULATIONS  
 
The information garnered from this local study enables us to establish a novel range of 
adipokine levels according to BMI for non-pregnant and pregnant Black South African women.  
This information is further, stratified according to type of pregnancy into normotensive 
pregnant, EOPE and LOPE pregnancies.  Moreover full stratification according to HIV status is 
for the first time recorded for Black South Africans. 
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In this local study, significantly lower levels of adiponectin, leptin and resistin in the pregnant 
cohort as compared to the non-pregnant cohort were found. TNF-α was only detected in the 
pregnant cohort. It is well recognised that pregnancy is a unique physiological state 
characterised by a temporary reversible insulin resistance and a modest level of immune 
elevation (Catalano et al., 1991, Buchanan et al., 1990, Ryan et al., 1985). Despite this, there is 
a dearth of literature regarding the adiponectin, leptin, resistin and TNF-α levels in healthy 
pregnant women.  Correlation of these levels with HIV infection and regarding variation 
according to the trimester of pregnancy is lacking. 
 
4.5.1 Adiponectin 
To our knowledge there has been thus far, only one prior study that attempts to establish the 
change in adiponectin level according to the trimester of pregnancy (Mazaki-Tovi et al., 2007). 
Limitations of this study was its small sample size (n = 80).  Although BMI was standardised in 
their study, they did not have a homogenous sample according to ethnicity.  In this local study 
standardisation for BMI was considered.  Moreover, this study was expedient in the fact that 
patients were all standardized according to ethnicity, sub-analysed according to BMI and all 
samples taken from the third trimester of pregnancy – one of the first such studies to be 
performed within South Africa as well as globally. This enables an establishment of a reference 
range for adipokines according to pregnancy type as well as HIV status in Black South African 
women in the third trimester pregnancy. 
 
In pregnancy the adiponectin levels range between 2.7 – 25 µg/ml compared to 3.5 – 22.4 
µg/ml in the non-pregnant (Nien et al., 2007). There was no difference demonstrated in the 
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adiponectin concentrations of non-pregnant and overweight pregnant females at any gestational 
age (Nien et al., 2007). However there was significantly lower adiponectin concentrations in 
overweight pregnant women compared to their normal weight counterparts. There was a trend 
of adiponectin decrease with advancing gestational age (Nien et al., 2007). 
 
The problem with the latter study however, was that the samples were randomly drawn from 
the NIH sample bank hence there was a heterogenous sample population.  Influence of race as 
well as sub-categorization for complicated pregnancies on adiponectin levels are serious 
drawbacks to the study.  
 
In contrast to the above study, the current study demonstrates a decrease in adiponectin levels 
between all pregnant cohorts. This may indicate that the relative insulin resistance of pregnancy 
has not been overcome. Raised serum adiponectin concentrations are associated with increased 
insulin sensitivity and glucose tolerance (Goldfine and Kahn, 2003). Supporting this concept is 
the fact that hypo-adiponectinaemia in pregnancy is a negative predictor of insulin resistance, 
beta cell dysfunction and increased risk of diabetes mellitus (Retnakaran et al., 2010). As 
explained above, other studies have demonstrated the negative correlation between adiponectin 
levels and insulin resistance.  
 
Another possible explanation for the difference in this study findings from other studies may be 
due to ethnic variation – the majority of the above mentioned studies were conducted on 
Caucasian participants. A study by Retnakaran et al., (2010) on South Asian women in 
pregnancy showed women of South Asian descent exhibited significantly reduced plasma 
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concentrations of adiponectin in pregnancy compared with their Caucasian and Asian 
counterparts, thus suggesting a greater risk for diabetes. 
 
4.5.2 Leptin  
Leptin is a satiety hormone hence it inhibits hunger and is secreted in proportion to adipose 
mass. In fact, the most important variable that determines circulating leptin concentrations in 
the body is fat mass (Speakman et al., 2002). Many studies have indicated that maternal 
peripheral leptin levels are enhanced during pregnancy (Helland et al., 1998, Jaquet et al., 
1998, Hardie et al., 1997, Highman et al., 1998, Butte et al., 1997, Schubring et al., 1997, 
Schubring et al., 1998, Sivan et al., 1998). 
 
A decline of leptin level after the second trimester and closer to parturition has been 
demonstrated (Henson and Castracane, 2006). These findings are consistent with a point out of 
time sampling in third trimester of pregnancy. 
 
Castellano et al., (2013) found an increase in leptin in the non-overweight (BMI ≤ 25kg/m
2
) as 
compared to the overweight pregnant participants (Castellano Filho et al., 2013).  Whilst most 
of this studys’ pregnant participants fell into the overweight/obese category the implication of 
low serum leptin in pregnant participants, could be attributed to maternal hunger in an attempt 
to meet the increased nutritional demands of pregnancy in the presence of a low adipose mass. 
The relatively high leptin levels in the non-regnant cohorts would be indicative of insulin 
sensitivity. The lack of difference in leptin concentration within the pregnant cohorts may be 
due to the obesity of this cohort.    
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4.5.3 TNF-α 
A 45% increase in TNF-α levels in late pregnancy has been reported (Kirwan et al., 2002). 
Further, other studies have shown that TNF-α is a predictor of insulin resistance in pregnancy 
(Clapp and Kiess, 2000, Beckmann et al., 1997). This is similar to and consistent with the low 
adiponectin levels demonstrated in this study, effectively showing that insulin resistance of 
pregnancy had not been overcome.  
 
4.5.4 Resistin 
Enlarged adipocytes release several products that can modify the body’s sensitivity to insulin. 
Free fatty acids and TNF-α cause insulin resistance, and leptin, which regulates energy balance, 
probably causes insulin sensitivity. Yet there is a paucity of information on the potential 
function of resistin or its homologs in pregnancy (Flier, 2001a).   
 
Further, in animal models, lower resistin mRNA in adipose tissue in different models of mouse 
obesity, such as diet-induced obesity, and in rat models characterized by hyperinsulinemia, 
hyperglycemia, hypertriglyceridemia, and hypertension have been demonstrated (Moore et al., 
2001a, Lay et al., 2001). This further, substantiates current study findings of a failure to 
overcome insulin resistance in the pregnant cohort. 
 
The levels of TNF-α, Leptin and Resistin were statistically significant different within the 
normotensive versus pre-eclamptic groups. Only Adiponectin failed to show statistically 
significant differences within the pregnancy subgroups 
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Both leptin and resistin were statistically lower and TNF-α higher in the preeclamptic cohort 
when compared to the normotensive cohort. During pregnancy, leptin is produced by both 
maternal and fetal adipose tissues, as well as by the placental trophoblast. Leptin induces 
human chorionic gonadotrophin production in trophoblast cells, regulates placental growth, 
enhances mitogenesis and stimulates amino acid uptake (Hauguel-de Mouzon et al., 2006). 
Most studies have found higher levels of leptin in pre-eclampsia (Hendler et al., 2005a). 
 
Placental leptin mRNA production is upregulated by tumour necrosis factor (TNF) -α and 
interleukin (IL)-6 (Nuamah et al., 2004).  It is thought that TNF-α is raised in pre-eclampsia in 
order to stimulate leptin production and increase nutrient supply to an underperfused placenta 
(Moore et al., 2003). 
 
It would be expected that leptin levels in this preeclamptic cohort ought to be increased as well. 
The above studies however did not consider the confounding factor of HIV – a study by Azzoni 
et al (2010) showed a negative correlation between leptin and viral load in HIV positive 
individuals (Azzoni et al., 2010). As this study did not account for viral loads, this may account 
for the seemingly unique findings of lowered leptin levels amongst the pre-eclamptic cohort in 
this study. 
 
The combination of a high viral load, together with the chronic inflammatory state induced by 
TNF may together account for patients with pre-eclampsia with low leptin levels. Studies on 
resistin levels in pre-eclampsia are few and conflicting – Hendler et al (2005) found no 
correlation between resistin and pre-eclampsia (Hendler et al., 2005a), whilst Cortelazzi et al 
(2007)  hypothesized that lower levels of resistin in PE might be related to a reduction in 
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placental production of the adipokines because of the smaller size of the placenta (Cortelazzi et 
al., 2007).  
 
However, statistically significant difference in placental weight between this studys’ EOPE and 
other pregnant cohorts were found. Deductive reasoning would suggest that there should also 
have a difference in resistin levels in the EOPE versus other pregnancy cohorts. Other reasons 
for low resistin levels in pregnancy would be the onset of gestational diabetes. Studies 
evaluating the links between insulin resistance, obesity and diabetes have reported low levels of 
resistin (Heilbronn et al., 2004, Savage et al., 2001, Way et al., 2001a). 
 
However the presence of diabetes was an exclusion criterion in this study. The answer may lie 
in the raised TNF-α levels – Fasshauer et al., (2001) found that TNF-α was a negative regulator 
of resistin and a 70-90% decrease in resistin mRNA and protein secretion was noted after TNF-
α administration (Fasshauer et al., 2001). 
 
The levels of adiponectin / leptin / resistin / TNF-α does not differ in women who develop early 
onset pre-eclampsia as compared to women who develop late onset pre-eclampsia. There was 
no statistically significant difference depicted in the levels of adiponectin/leptin/tnf or resistin 
between the EOPE vs LOPE cohorts. This may indicate that there is a similar disease process 
occurring, but more likely the impact of HIV has a confounding effect. Further, since only one 
time point in pregnancy was assessed firm conclusions cannot be drawn. 
 
 - 122 - 
4.6 ADIPONECTIN, LEPTIN, RESISTIN AND TNF-α LEVELS IN NON PREGNANT 
HIV PATIENTS VS PREGNANT HIV PATIENTS ACCORDING TO CD4 COUNTS 
This study generated the following findings: 
 non pregnant HIV negative participants had lower adiponectin levels than the 
normotensive HIV positive / and non-pregnant HIV positive participants respectively 
 The non-pregnant HIV positive participants had lower leptin levels than the 
normotensive HIV positive participants 
 The non-pregnant HIV positive participants had lower resistin levels than the 
normotensive HIV positive participants. 
 The mean maternal age is lower in normotensive HIV negative participants than that of 
non-pregnant HIV negative and non-pregnant HIV positive participants. 
 
The levels of adiponectin in HIV-positive ARV naive patients were  lower  compared to the  
healthy subjects (Li et al., 2011). In ARV treated patients, the levels of adiponectin is lower 
than in HIV- negative patients. Both protease inhibitors (PIs) and nucleoside reverse 
transcriptase inhibitors (NRTIs) alter adipokine secretion from human subcutaneous adipocytes 
(Lagathu et al., 2007). Further,, an interesting study by Sankale et al., (2006) showed that 
human subcutaneous adipocytes exposed to HIV-1 dramatically increased the secretion of 
adiponectin (Sankale et al., 2006). 
 
In this study, a statistically significant difference in the levels of adiponectin/leptin/resistin and  
TNF-α in HIV positive patients within the non-pregnant versus pregnant population matched 
for CD4 count, was found. Within the pre-eclamptic cohort there was no statistically significant 
difference in EOPE versus LOPE when matched to CD4 count. In a similar vein the study by 
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Arama et al., (2012) also showed no difference in adipokine, leptin or resistin levels when 
comparing healthy treatment naive HIV positive patients compared to treated HIV positive 
patients (Arama et al., 2012). However, the latter study reported significantly higher levels of 
TNF-α in participants with persistent viral load. It is not possible to comment on this aspect as 
viral load assessment was not assessed in this local study as it is not a standard of care practice. 
Research with a larger number of patients and prospective study designs may be required to 
draw statistically significant and relevant conclusions regarding the association between 
adipokines and HIV replication.   
 
 
The difference in levels of adiponectin/ leptin / resistin / TNFα in women who develop early 
onset pre-eclampsia as compared to women who develop late onset pre-eclampsia are not 
altered by the HIV status of the patients 
 
This study did not show any statistical significance in the levels of adiponectin/leptin/TNF-α/or 
resistin among the pregnant cohorts irrespective of CD4 counts and ARV usage. The 
lipodystrophy syndrome of HIV patients has been well documented in the literature. It is 
characterised by fat redistribution (lipodystrophy or lipoatrophy), fat loss from the face, 
buttocks and extremities (lipoatrophy), and mixed fat disturbances (lipodystrophy and 
lipoatrophy (Carr et al., 1998a, Carr et al., 1998c, Saint-Marc et al., 1999, Behrens et al., 2000, 
Hakeem et al., 2008). As mentioned earlier, there was no statistically significant differences in 
mid upper arm circumference or triceps skinfold thickness between the EOPE and LOPE 
cohorts. This may account for the similar levels of adiponectin/leptin/resistin and TNF-α in 
both cohorts. 
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4.7 ADIPONECTIN, LEPTIN, RESISTIN AND TNF-α LEVELS ACCORDING TO BMI 
There were no statistically significant differences in levels of TNF-α, Leptin, and Resistin when 
compared across subdivisions of BMI in the non-pregnant population. Adiponectin did show 
statistically significant differences across BMI subdivisions in the non-pregnant population. 
Further, there were statistically significant differences in BMI between the non- pregnant and 
pregnant cohorts. 
 
There was no statistically significant differences in the levels of TNF-α, Adiponectin, Leptin 
and Resistin in the pregnant population across the subdivisions of BMI. Adiponectin levels 
have been shown to be paradoxically lower in obese patients when compared to non obese 
patients (Arita et al., 1999; Hu et al., 1996). Further,, it has been shown that weight reduction 
in obese individuals is accompanied by an increase in plasma adiponectin concentrations 
(Esposito et al., 2003). This a difficult area of interpretation as there are no standardised BMI 
charts for pregnancy globally. 
 
4.8 LIMITATIONS OF THE STUDY 
Blood samples were only drawn for adipokine assessment at one time point in the study ie., in 
the third trimester. Preferably patients should be recruited in the pre-pregnancy state and 
followed up through all three trimesters. However, in the current setting, patients only present 
to a referral hospital late in pregnancy. An assessment of viral load in the pre-pregnancy and 
through each trimester would have strengthened the study. This however, this was not possible 
as it is not standard of care practice in South Africa.  These are limitations imposed by the 
Department of Health.  It must be acknowledged that the findings of this study are correlative 
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as there are mechanistic experiments included in this thesis to outline the role of the tested 
factors in pre-eclampsia with or without HIV. 
 
4.9 STRENGTHS OF THE STUDY 
The strengths of this study include its strict inclusion and exclusion criteria thus ensuring as 
homogenous a population as possible. The study is innovative because adipokine levels are 
compared across non-pregnant, normotensive-pregnant and pre-eclamptic women associated 
with HIV infection. It is also novel in that it correlates adipokine levels with HIV status. This 
pioneering study establishes a baseline for adipokines across the non-pregnant, normotensive-
pregnant and pre-eclamptic women associated with and without HIV infection in Black South 
African women. 
 
4.10 CLINICAL IMPLICATIONS OF THE STUDY 
To our knowledge it is the first such study to address the three aspects of obesity, HIV and pre-
eclampsia and their inter-relationship. It is a relatively large study and establishes the marked 
difference in adiponectin/leptin/resistin and TNF-α levels between normotensive pregnancy and 
pre-eclampsia. It is plausible to implicate the deficient placentation with adipokine 
dysregulation as the pathological process of EOPE development compared to that of LOPE. 
 
4.11 FUTURE RESEARCH 
Future research should assess adipokines from pre-pregnancy across all 3 trimesters of 
pregnancy. In addition to the maternal serum levels, cord blood should also be assessed for 
these adipokines. Viral load, and ARV usage should be specifically included irrespective if it is 
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not a standard of care practice. Moreover, placental tissue and umbilical cord should be 
assessed by immunohistochemistry for the paracrine secretion of these adipokines. 
 
4.12 CONCLUSION 
This study was expedient in the fact that patients were all standardized according to ethnicity, 
sub-analysed according to BMI and all samples taken from the third trimester of pregnancy – 
one of the first such studies to be performed within South Africa as well as globally.  The study 
reports significant differences in the BMI of the non-pregnant and pregnant groups, but no 
significant differences within the pregnant cohorts. In conclusion this study establishes an 
adipokine baseline for future reference with regards to South African Black pregnant and non-
pregnant women.  Albeit at term, this study shows a statistically significant difference in the 
levels of adiponectin/leptin/resistin and TNF-α in HIV positive patients within the non-
pregnant versus pregnant population. Within the pre-eclamptic cohort there was no statistically 
significant difference in EOPE versus LOPE. The ubiquitous HIV infection, high pre-eclampsia 
and obesity prevalence in South Africa, warrants this novel study that reconnoiters the 
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ADDENDUM 2 INSTITUTIONAL ETHICS APPROVAL 
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ADDENDUM 4 CONSENT DOCUMENT 
Title of Study: The Role of adiponectin, TNF, leptin and resistin in HIV associated pre-
eclamptics 
 
Good day.  Miss/ Mrs ________________. My name is __________________ 
Thank you for giving me the time to speak to you. 
 
My colleagues and I are currently doing research on high blood pressure and pregnancy. 
Research is just the process to learn the answer to a question. In this study, we want to learn 
what causes this high blood pressure in pregnant women and what factors may be involved in 
causing this to happen.   
 
When you are pregnant, the baby growing inside of you actually receives nutrition from a piece 
of tissue that is attached to your womb called the placenta or after birth. We think that certain 
substances/hormones made in the fat affect the way that this placenta develops and leads to 
high blood pressure. 
We are inviting you to participate and require your permission to be included in this research 
study.  This is what your role will be in this study.  We need you to donate a blood sample to 
perform some laboratory tests on it.  This will not harm you or your baby in any way. Please be 
aware that an experienced doctor will be available to draw out the blood. The taking of the 
blood will be done at the same time as the normal or routine blood tests are done to avoid many 
venipunctures. The taking of blood may cause minor discomfort. 
 
 All these samples are being collected here in this hospital from South African woman and will 
be studied at the Nelson Mandela Medical School.  You will not directly benefit from this 
research in this pregnancy but other women or you in the future may benefit. The taking of the 
bloods will not interfere with the treatment you will be getting. 
 
Please note that this research is being done for a higher degree or university qualification. The 
results of this will benefit medical science. 
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Please remember that you can refuse to enter the study and if you do you will not be 
disadvantaged in any way and all our discussions are private and confidential. 
 
Thank you for your time and assistance in this study. 
 
Islwoko sokufundwayo: 
Ngiyabingelela Nkosazane / Nkosikazi. Igama lami ngingu ___________________________ 
Ngiyabonga ukuthola ithuba lokukhuluma nawe 
 
Mina nozakwethu senza ucwaningo ngomfutho wegazi nokukhulelwa. Ucwaningo ngomfutho 
nokuphendulwa kwemibuzo. Kulolucwaningo sifuna ukathola ukuthi ubangwa yini umfutho 
ophezulu wegazi komama abakhulelwe nemiphumela yokuthi loko kwenzeke. 
 
Uma ukhulelwe ingane ekhula ngaphakathi ithola ukudla ngesicubu senyama esinamathele 
esibelethweni esibizwa ngomzanyana. Sicabangela ukuthi ukulakheka kwamafutha 
kuphazamisa indlela umzanyana akhula ngayo lokho okwenza ukwenyuka komfutho wegazi. 
Sifisa ukukumema sisebenzisane nawe kulolucwa-ningo. Yilokhu ozosenzela khona. Sicela 
usinikelele ngegazi lokwenza lokuwaningo. Lokhu akuzukukulimaza wena noma umntwana 
nanoma ngayiphi indlela. Sifisa wazi ukuthi udokotela oqeqeshekile ozobakhona ukuthatha 
igazi. Ukuthathwa kwegazi kokwenziwa kanyekanye nalokhe okujwayelekile ukuvimbela 
ukujovwa kaningi. Ukuthathwa kwegazi kungenza uzizwe ungemnandi kahle. 
 
Leziziboniso eziqoqwe kwabesifazane base mzansi Africa kuzofundwa nguzo eskoleni 
sobudokotela iNelson Mandela. Akukho wena ozokuthola ngqo ngalolucwaning kadwa abanye 
besifazane noma wena ngokuzayo. Ukuthathwa kwegazi akuzulwba namthelela kwimithi 
oyithdayo. 
Lolucwaningo lwenzelwe ezemfundo ephakeme. Imiphumda izosiza kwezobudokotela. 
Khumbula ukuthi ungakwazi ukunqaba ukungenela lolucwaningo futhi ngalokho akukho 
okokulahlekela. 
 
Siyabonga isikhethi sakho nokusiza ngalesesisifundo.  
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Information for non pregnant women: 
Title of Study: The Role of adiponectin, TNF, leptin and resistin in HIV associated pre-
eclamptics 
 
Good day.  Miss/ Mrs ________________. My name is __________________ 
Thank you for giving me the time to speak to you. 
 
My colleagues and I are currently doing research on high blood pressure and pregnancy and 
HIV. Research is just the process to learn the answer to a question. In this study, we want to 
learn what causes this high blood pressure in pregnant women and what factors may be 
involved in causing this to happen.  We also want to know how HIV may also lead to problems 
with high blood pressure. 
When you are pregnant, the baby growing inside of you actually receives nutrition from a piece 
of tissue that is attached to your womb called the placenta or after birth. We think that certain 
substances/hormones made in the fat affect the way that this placenta develops and leads to 
high blood pressure. We also think that HIV on its own can increase these substances that leads 
to high blood pressure when you are not pregnant. 
We are inviting you to participate and require your permission to be included in this research 
study.  This is what your role will be in this study.  We need you to donate a blood sample to 
perform some laboratory tests on it.  This will not harm you. Please be aware that an 
experienced doctor will be available to draw out the blood. The taking of the blood will be done 
at the same time as the normal or routine blood tests are done to avoid many venipunctures. 
The taking of blood may cause minor discomfort. 
All these samples are being collected here in this hospital from South African woman and will 
be studied at the Nelson Mandela Medical School.  You will not directly benefit from this 
research but other women or you in the future may benefit. The taking of the bloods will not 
interfere with the treatment you will be getting. 
 Please note that this research is being done for a higher degree or university qualification .The 
results of this will benefit medical science. 
Please remember that you can refuse to enter the study and if you do you will not be 
disadvantaged in any way and all our discussions are private and confidential. 
 
Thank you for your time and assistance in this study 
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Ulwazi kwabesifazane abangakhulelwe 
Ngiyabingelela Nkosazane / nkosikazi___________________________________________ 
Igama lami ngingu______________________________________________. Ngibonga ithuba 
ongipha lona lokuxoxa nawe.  
 
Mina nozakwethu senza ucwaningo ngonifutho ophezulu wegazi, ukukhulelwa nesandulele 
ngculazi. Ubwaningo indlela yokufunda ukuphendula imibuzo. Kulokufunda sifuna ukuthola 
izimbangela zomfutho ophezulu wegazi kwabesifazane abakhulelwe. 
 
Uma ukhulelwe, ingane ekhula ngaphakathi ithola ukudla ngesicubu senyama esinamathele 
kwisibeletho esbizwa ngomzanyana. Sicabagela ukuthi ukwakheka kwamafutha ikhona nokuthi 
isandilela ngculazi ngokwaso singabangela ukwenyaka komfutho wegazi noma ungakhulelwe. 
 
Siyakumena ngokwemvume yakho ukuba ube yingxenye yalokcwaningo. Yilokhu ozosisiza 
ngakho kulesisifundo. Sifisa unikele ngegazi elizosetshenzi swa ukuyohlolwa. Lokhu 
akunabungozi kuwe. Qaphela ukuthi udokotela oqeqehekile ozobekhona ukuthatha igazi. 
Ukuththwa kwegazi kuzokwenziwa ngasikhathi sinye namanye amagazi ukubalekela ukujovwa 
kiningi. Ukuthathwa kwegazi kungenza uzizwe ungemnandi kahle.  
 
Leziziboniso eziqoqwe kwabesifazane baseMzansi Afrika kuzofundwa ngazo esikoleni 
sobudokotela iNelson Mandela. Akukho lutho wena ozokuthola ngqo kulolucwaningo kodwa 
abanye besifazane noma wena ngokuzayo. Ukuthathwa kwegazi akuzukuba namthelela 
kwimithi oyitholayo. 
 
Lolucwaningo lwenzelwe ezenfundo ephakeme. Imiphumela iyosiza kwezobudoktela. 
 
Khumbula ungakwazi ukunqaba ukungenela lolcwaningo futhi ngalokho akukho 
okokulahlekela lolucwaningo futhi ngalokho akukho okokulahlekela. Okoxoxiwe kuzogcinwa 
kuyimfihlo kuvikelekile. 
 
Sibonga ukubambisana kulesisifundo. 
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ADDENDUM 5 PATIENT DATA FORM 
 
THE ROLE OF ADIPONECTIN / RESISTIN / LEPTIN / TNFα IN 
HIV-ASSOCIATED 
PRE-ECLAMPSIA      
     Study no: 
 
   IP number 
Category (tick): (more than 1 catergory may require a tick) 
1. Pre-eclamptic HIV +ve CD4 < 350:   □ 
2. Pre-eclamptic HIV +ve CD4 > 350:   □ 
3. Pre-eclamptic HIV -ve CD4 :             □ 
4. Pregnant Normotensive HIV +ve CD4 < 350:   □ 
5. Pregnant Normotensive HIV +ve CD4 > 350:    □ 
6. Pregnant Normotensive HIV -ve:                       □ 
7. Onset pre-eclampsia before 34 wks   □ 
8. Onset of pre-eclampsia at or after 34wks □ 
9. Normotensive , Non Pregnant              □ 
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THE FOLLOWING BLOODS MUST BE TAKEN FOR THE PURPOSES 
OF THIS STUDY. PLEASE TICK IF THE BLOODS TAKEN  
1. ADIPONECTIN                       □ 
2. LEPTIN                                    □ 
3. RESISTIN                               □ 
4. TNFα                                    □                 
                
          General hospital information 
Admission date  RKK no.  
 
Demographics 




Rural Urban  




HIV Status +ve -ve 
CD4 counts   
   
Anti Retroviral therapy Yes no 
HAART   
PMCTC   
 





Type of Treatment Yes No 
Magnesium sulphate   
Aldomet   
Monoohydralazine   
Nifedipine   
Dihydralazine (nepresol)   
Labetalol   
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Others   
 
Clinical Data  
Parity P:         G: Weeks gestation on admission  
Reason for previous pregnancy loss (If any) 
Highest BP Systolic:                     Diastolic: 




Triceps skin fold thickness 













Red cell count  White cell count  
Haemoglobin  Neutrophils  
Haematocrit  Lymphocytes  
Mean cell volume  Monocytes  
Mean cell Hb  Eosinophils  
Platelets  Basophils  
Urea and 
electrolyte 
Sodium  Urea  
Potassium  Creatinine  
Chloride  Anion gap  




Total protein  Alkaline phos  
Albumin  AST  
Globulin  ALT  
Alb : Glob  LDH  
Total bilirubin    
 
Antenatal Fetal Investigations  









Weeks of gestation at time of  birth  
 - 153 - 
Date of birth     
 









Combination of Maternal 




 Explain above if 
relevant 
 
Explain above if 
Relevant 
 
Explain above if relevant 
Diagnosis:  
Eclampsia, 






Normal vaginal Caesarean 
Spontaneous  Elective  











Baby details at birth 
APGAR 1 min  5 min  
Baby (tick) Live  Stillborn  
 Perinatal death 
(1st 7days) 
 Neonatal death 








Shape Normal abnormal 
Weight (grams)  
Diameter (cm)  
Thickness (cm) Less than 2cm 2-3cm More than 4 
Colour Maternal surface Dark Maroon Pale 
Fetal surface Dark  Pale 





infarcted tissue  
clear mild severe 
Colour of infarcts 
(if present) 
Pale grey Very dark Both 
Clots (maternal 
surface) tick 
None few many 
Umbilical cord Point of 
attachment  
central peripheral 
Length Less than 30 
cm 
30-90 cm Greater than 
90 cm 
No of vessels 3 2 
Oedema present absent 
 
FOLLOW UP DATA PRIOR TO DISCHARGE FROM HOSPITAL 
Date:____________        Inpatient / Outpatient visit: _____________ 
 
Oedema (tick) ankle Up to knee Up to groin Generalised (facial) 
 
Any other observations/clinical data/information of relevance for mother: 











formula  Breast flash 
heating 
not fed TPN 
Cranial scan  
 
Morbidities in early NN period 
Resp Distress  
 
HMD, TTN, Pneum ?Mas, other  
CNS  
 






hypothermia,   





  eye, 
  umbilicus, 
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  Suspected sepsis   





  Septicaemia  (positive 
BC), 
  meningitis (positive 
culture 
  NEC, 
  susp sepsis + low wcc 








Any other observations/clinical data/information of relevance for child: 
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FOLLOW UP DATA AFTER DISCHARGE FROM HOSPITAL 
 
Date:____________        Inpatient / Outpatient visit: _____________ 
 
Oedema (tick) Ankle Up to knee Up to groin Generalised (facial) 
 
Baby weight: _______________ Maternal BP: ____________________ 
  







HIV status of baby 6 
weeks post delivery 
HIV +ve (PCR) HIV –ve 
CD4 count    
Baby NVP and AZT  
Bactrim yes/no 
 (7 days or 28 days) 
   
 
















Alive ill   - record morbidities as 
above 
 
Minor infections, HIV related 
infections,ROP and Audiology if small 
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ADDENDUM 6 COLLABORATION WITH STATENS SERUM INSTITUT  
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ADDENDUM 7 EXPORT PERMIT- SA TO COPENHAGEN, DENMARK 
 
